Search

Your search keyword '"Aleinikova, O"' showing total 165 results
Start Over Author "Aleinikova, O"
165 results on '"Aleinikova, O"'

4. Correction: Myeloablative conditioning for allo-HSCT in pediatric ALL: FTBI or chemotherapy?—A multicenter EBMT-PDWP study (Bone Marrow Transplantation, (2020), 55, 8, (1540-1551), 10.1038/s41409-020-0854-0)

Author

Willasch A. M., Willasch, A, Peters, C, Sedlacek, P, Dalle, J, Kitra-Roussou, V, Yesilipek, A, Wachowiak, J, Lankester, A, Prete, A, Hamidieh, A, Ifversen, M, Buechner, J, Krivan, G, Hamladji, R, Diaz-de-Heredia, C, Skorobogatova, E, Michel, G, Locatelli, F, Bertaina, A, Veys, P, Dupont, S, Or, R, Gungor, T, Aleinikova, O, Sufliarska, S, Sundin, M, Rascon, J, Kaare, A, Nemet, D, Fagioli, F, Klingebiel, T, Styczynski, J, Bierings, M, Nagy, K, Abecasis, M, Afanasyev, B, Ansari, M, Vettenranta, K, Alseraihy, A, Chybicka, A, Robinson, S, Bertrand, Y, Kupesiz, A, Ghavamzadeh, A, Campos, A, Pichler, H, Dalissier, A, Labopin, M, Corbacioglu, S, Balduzzi, A, Galimard, J, Bader, P, Willasch A. M., Peters C., Sedlacek P., Dalle J. -H., Kitra-Roussou V., Yesilipek A., Wachowiak J., Lankester A., Prete A., Hamidieh A. A., Ifversen M., Buechner J., Krivan G., Hamladji R. -M., Diaz-de-Heredia C., Skorobogatova E., Michel G., Locatelli F., Bertaina A., Veys P., Dupont S., Or R., Gungor T., Aleinikova O., Sufliarska S., Sundin M., Rascon J., Kaare A., Nemet D., Fagioli F., Klingebiel T. E., Styczynski J., Bierings M., Nagy K., Abecasis M., Afanasyev B., Ansari M., Vettenranta K., Alseraihy A., Chybicka A., Robinson S., Bertrand Y., Kupesiz A., Ghavamzadeh A., Campos A., Pichler H., Dalissier A., Labopin M., Corbacioglu S., Balduzzi A., Galimard J. -E., Bader P., Willasch A. M., Willasch, A, Peters, C, Sedlacek, P, Dalle, J, Kitra-Roussou, V, Yesilipek, A, Wachowiak, J, Lankester, A, Prete, A, Hamidieh, A, Ifversen, M, Buechner, J, Krivan, G, Hamladji, R, Diaz-de-Heredia, C, Skorobogatova, E, Michel, G, Locatelli, F, Bertaina, A, Veys, P, Dupont, S, Or, R, Gungor, T, Aleinikova, O, Sufliarska, S, Sundin, M, Rascon, J, Kaare, A, Nemet, D, Fagioli, F, Klingebiel, T, Styczynski, J, Bierings, M, Nagy, K, Abecasis, M, Afanasyev, B, Ansari, M, Vettenranta, K, Alseraihy, A, Chybicka, A, Robinson, S, Bertrand, Y, Kupesiz, A, Ghavamzadeh, A, Campos, A, Pichler, H, Dalissier, A, Labopin, M, Corbacioglu, S, Balduzzi, A, Galimard, J, Bader, P, Willasch A. M., Peters C., Sedlacek P., Dalle J. -H., Kitra-Roussou V., Yesilipek A., Wachowiak J., Lankester A., Prete A., Hamidieh A. A., Ifversen M., Buechner J., Krivan G., Hamladji R. -M., Diaz-de-Heredia C., Skorobogatova E., Michel G., Locatelli F., Bertaina A., Veys P., Dupont S., Or R., Gungor T., Aleinikova O., Sufliarska S., Sundin M., Rascon J., Kaare A., Nemet D., Fagioli F., Klingebiel T. E., Styczynski J., Bierings M., Nagy K., Abecasis M., Afanasyev B., Ansari M., Vettenranta K., Alseraihy A., Chybicka A., Robinson S., Bertrand Y., Kupesiz A., Ghavamzadeh A., Campos A., Pichler H., Dalissier A., Labopin M., Corbacioglu S., Balduzzi A., Galimard J. -E., and Bader P.

Abstract

The article “Myeloablative conditioning for allo-HSCT in pediatric ALL: FTBI or chemotherapy?—A multicenter EBMT-PDWP study,” written by Andre Manfred Willasch, Christina Peters, Petr Sedlácek, Jean-Hugues Dalle, Vassiliki Kitra-Roussou, Akif Yesilipek, Jacek Wachowiak, Arjan Lankester, Arcangelo Prete, Amir Ali Hamidieh, Marianne Ifversen, Jochen Buechner, Gergely Kriván, Rose-Marie Hamladji, Cristina Diaz-de-Heredia, Elena Skorobogatova, Gérard Michel, Franco Locatelli, Alice Bertaina, Paul Veys, Sophie Dupont, Reuven Or, Tayfun Güngör, Olga Aleinikova, Sabina Sufliarska, Mikael Sundin, Jelena Rascon, Ain Kaare, Damir Nemet, Franca Fagioli, Thomas Erich Klingebiel, Jan Styczynski, Marc Bierings, Kálmán Nagy, Manuel Abecasis, Boris Afanasyev, Marc Ansari, Kim Vettenranta, Amal Alseraihy, Alicja Chybicka, Stephen Robinson, Yves Bertrand, Alphan Kupesiz, Ardeshir Ghavamzadeh, Antonio Campos, Herbert Pichler, Arnaud Dalissier, Myriam Labopin, Selim Corbacioglu, Adriana Balduzzi, Jacques-Emmanuel Galimard, Peter Bader, on behalf of the EBMT Paediatric Diseases Working Party, was originally published online first without Open Access. After publication in volume 55, issue 8, page 1540–1551, the author decided to opt for Open Choice and to make the article an Open Access publication. Therefore, the copyright of the article has been changed to © The Author(s) 2020 and the article is forthwith distributed under the terms of the Creative Commons Attribution 4.0 InternationalS License, which permits use, sharing, adaptation, distribution, and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third-party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Comm

Published
2021

5. Low-intensity therapy cures over 40 % of children with rapid Flow-MRD responding ALL: the ALL-MB 2008 trial results

Author

Popov, A., primary, Henze, G., additional, Roumiantseva, Yu., additional, Budanov, O., additional, Belevtsev, M., additional, Verzhbitskaya, T., additional, Boyakova, E., additional, Movchan, L., additional, Tsaur, G., additional, Fadeeva, M., additional, Lagoyko, S., additional, Zharikova, L., additional, Myakova, N., additional, Litvinov, D., additional, Khlebnikova, O., additional, Streneva, O., additional, Stolyarova, E., additional, Ponomareva, N., additional, Novichkova, G., additional, Fechina, L., additional, Aleinikova, O., additional, and Karachunskiy, A., additional

Published
2022
Full Text
View/download PDF

6. Prognostic value of minimal residual disease measured by flow-cytometry in two cohorts of infants with acute lymphoblastic leukemia treated according to either MLL-Baby or Interfant protocols

Author

Popov, A, Buldini, B, De Lorenzo, P, Disaro, S, Verzhbitskaya, T, Movchan, L, Giarin, E, Shorikov, E, Di Meglio, A, Tsaur, G, Parasole, R, Miakova, N, Boichenko, E, Kondratchik, K, Aleinikova, O, Karachunskiy, A, Roumiantsev, A, Locatelli, F, Biondi, A, Pieters, R, Valsecchi, M, Fechina, L, Basso, G, Popov A., Buldini B., De Lorenzo P., Disaro S., Verzhbitskaya T., Movchan L., Giarin E., Shorikov E., Di Meglio A., Tsaur G., Parasole R., Miakova N., Boichenko E., Kondratchik K., Aleinikova O., Karachunskiy A., Roumiantsev A., Locatelli F., Biondi A., Pieters R., Valsecchi M. G., Fechina L., Basso G., Popov, A, Buldini, B, De Lorenzo, P, Disaro, S, Verzhbitskaya, T, Movchan, L, Giarin, E, Shorikov, E, Di Meglio, A, Tsaur, G, Parasole, R, Miakova, N, Boichenko, E, Kondratchik, K, Aleinikova, O, Karachunskiy, A, Roumiantsev, A, Locatelli, F, Biondi, A, Pieters, R, Valsecchi, M, Fechina, L, Basso, G, Popov A., Buldini B., De Lorenzo P., Disaro S., Verzhbitskaya T., Movchan L., Giarin E., Shorikov E., Di Meglio A., Tsaur G., Parasole R., Miakova N., Boichenko E., Kondratchik K., Aleinikova O., Karachunskiy A., Roumiantsev A., Locatelli F., Biondi A., Pieters R., Valsecchi M. G., Fechina L., and Basso G.

Published
2020

7. Hematopoietic stem cell transplantation for Wiskott-Aldrich syndrome: an EBMT Inborn Errors Working Party analysis

Author

Albert, M. H., Slatter, M. A., Gennery, A. R., Gungor, T., Bakunina, K., Markovitch, B., Hazelaar, S., Sirait, T., Courteille, V., Aiuti, A., Aleinikova, O. V., Balashov, D., Bernardo, M. E., Bodova, I., Bruno, B., Cavazzana, M., Chiesa, R., Fischer, A., Hauck, F., Ifversen, M., Kalwak, K., Klein, C., Kulagin, A., Kupesiz, A., Kuskonmaz, B., Lindemans, C. A., Locatelli, Franco, Lum, S. H., Maschan, A., Meisel, R., Moshous, D., Porta, F., Sauer, M. G., Sedlacek, P., Schulz, A., Suarez, F., Vallee, T. C., Winiarski, J. H., Zecca, M., Neven, B., Veys, P., Lankester, A. C., Locatelli F. (ORCID:0000-0002-7976-3654), Albert, M. H., Slatter, M. A., Gennery, A. R., Gungor, T., Bakunina, K., Markovitch, B., Hazelaar, S., Sirait, T., Courteille, V., Aiuti, A., Aleinikova, O. V., Balashov, D., Bernardo, M. E., Bodova, I., Bruno, B., Cavazzana, M., Chiesa, R., Fischer, A., Hauck, F., Ifversen, M., Kalwak, K., Klein, C., Kulagin, A., Kupesiz, A., Kuskonmaz, B., Lindemans, C. A., Locatelli, Franco, Lum, S. H., Maschan, A., Meisel, R., Moshous, D., Porta, F., Sauer, M. G., Sedlacek, P., Schulz, A., Suarez, F., Vallee, T. C., Winiarski, J. H., Zecca, M., Neven, B., Veys, P., Lankester, A. C., and Locatelli F. (ORCID:0000-0002-7976-3654)

Abstract

Allogeneic hematopoietic stem cell transplantation (HSCT) is a potentially curative treatment for patients affected by Wiskott-Aldrich syndrome (WAS). Reported HSCT outcomes have improved over time with respect to overall survival, but some studies have identified older age and HSCT from alternative donors as risk factors predicting poorer outcome. We analyzed 197 patients undergoing transplant at European Society for Blood and Marrow Transplantation centers between 2006 and 2017 who received conditioning as recommended by the Inborn Errors Working Party (IEWP): either busulfan (n = 103) or treosulfan (n = 94) combined with fludarabine ± thiotepa. After a median follow-up post-HSCT of 44.9 months, 176 patients were alive, resulting in a 3-year overall survival of 88.7% and chronic graft-versus-host disease (GVHD)-free survival (events include death, graft failure, and severe chronic GVHD) of 81.7%. Overall survival and chronic GVHD-free survival were not significantly affected by conditioning regimen (busulfan- vs treosulfan-based), donor type (matched sibling donor/matched family donor vs matched unrelated donor/mismatched unrelated donor vs mismatched family donor), or period of HSCT (2006-2013 vs 2014-2017). Patients aged <5 years at HSCT had a significantly better overall survival. The overall cumulative incidences of grade III to IV acute GVHD and extensive/moderate/severe chronic GVHD were 6.6% and 2.1%, respectively. Patients receiving treosulfan-based conditioning had a higher incidence of graft failure and mixed donor chimerism and more frequently underwent secondary procedures (second HSCT, unconditioned stem cell boost, donor lymphocyte infusion, or splenectomy). In summary, HSCT for WAS with conditioning regimens currently recommended by IEWP results in excellent survival and low rates of GVHD, regardless of donor or stem cell source, but age ≥5 years remains a risk factor for overall survival.

Published
2022

8. Efficacy and toxicity of dexamethasone vs methylprednisolone—long-term results in more than 1000 patients from the Russian randomized multicentric trial ALL-MB 2002

Author

Karachunskiy, A, Roumiantseva, J, Lagoiko, S, Bührer, C, Tallen, G, Aleinikova, O, Bydanov, O, Korepanova, N, Bajdun, L, Nasedkina, T, von Stackelberg, A, Novichkova, G, Maschan, A, Litvinov, D, Myakova, N, Ponomareva, N, Kondratchik, K, Fechina, L, Streneva, O, Judina, N, Scharapova, G, Shamardina, A, Gerbek, I, Shapochnik, A, Rumjanzew, A, and Henze, G

Published
2015
Full Text
View/download PDF

9. Techniques for visualizing students’ thinking in russian language lessons

Author

Aleinikova, O. S.

Subjects
мышление, обучение русскому языку, визуализация, visual literacy, thinking, приём визуализации, интеллектуальные операции, визуальная грамотность, Russian language teaching, visualization technique, visualization, intellectual operations
Abstract

В статье рассматривается роль визуализации в повышении уровня осмысленности при овладения школьниками учебным материалом по русскому языку. Цель работы – выявить возможности использования отдельных приёмов визуализации мышления школьников в процессе обучения русскому языку. Используемые методы: аналитический, сравнительно-сопоставительный, моделирование. В результате проведённого исследования были раскрыты преимущества применения средств наглядности для решения задач интеллектуального развития учащихся в процессе обучения. Приведены примеры методических приёмов визуализации информации, активизирующих познавательную и речемыслительную деятельность обучающихся. Обоснована значимость визуальной грамотности школьников как части их информационной культуры. = The article reveals the role of visualization in increasing the level of meaningful-ness while students’ learning the Russian language material. The aim of the research is to identify the possibilities of using certain methods of visualizing students’ thinking in the process of teaching Russian. Methods used include analytical method, comparative method, modeling. As a result, the advantages of using visual aids to fulfil the tasks on students’ intellectual development in the learning process have been revealed. The examples of methodological techniques of visualizing information that activate students’ cognitive and speech activity have been given. The importance of students’ visual literacy as a part of their information culture has been substantiated.

Published
2022

15. Allogeneic hematopoietic stem cell transplantation in leukocyte adhesion deficiency type I and III

Author

Bakhtiar, S., Salzmann-Manrique, E., Blok, H.J., Eikema, D.J., Hazelaar, S., Ayas, M., Toren, A., Goldstein, G., Moshous, D., Locatelli, F., Merli, P., Michel, G., Ozturk, G., Schulz, A., Heilmann, C., Ifversen, M., Wynn, R.F., Aleinikova, O., Bertrand, Y., Tbakhi, A., Veys, P., Karakukcu, M., Kupesiz, A., Ghavamzadeh, A., Handgretinger, R., Unal, E., Perez-Martinez, A., Gokce, M., Porta, F., Aksu, T., Karasu, G., Badell, I., Ljungman, P., Skorobogatova, E., Yesilipek, A., Zuckerman, T., Bredius, R.R.G., Stepensky, P., Shadur, B., Slatter, M., Gennery, A.R., Albert, M.H., Bader, P., Lankester, A., Pediat Dis Working Party, and Inborn Errors Working Party EBMT

Subjects
surgical procedures, operative
Abstract

Type I and III leukocyte adhesion deficiencies (LADs) are primary immunodeficiency disorders resulting in early death due to infections and additional bleeding tendency in LAD-III. The curative treatment of LAD-I and LAD-III is allogeneic hematopoietic stem cell transplantation (allo-HSCT). In this retrospective multicenter study, data were collected using the European Society for Blood and Marrow Transplantation registry; we analyzed data from 84 LAD patients from 33 centers, all receiving an allo-HSCT from 2007 to 2017. The 3-year overall survival estimate (95% confidence interval [CI]) was 83% (74-92) for the entire cohort: 84% (75-94) and 75% (50-100) for LAD-I and LAD-III, respectively. We observed cumulative incidences (95% CI) of graft failure (GF) at 3 years of 17% (9%-26%) and grade II to IV acute graft-versus-host disease (aGVHD) at 100 days of 24% (15%-34%). The estimate (95% CI) at 3 years for GF- and GVHD-II to IV-free survival as event-free survival (EFS) was 56% (46-69) for the entire cohort; 58% (46-72) and 56% (23-88) for LAD-I and LAD-III, respectively. Grade II to IV acute GVHD was a relevant risk factor for death (hazard ratio 3.6; 95% CI 1.4-9.1; P = .006). Patients' age at transplant >= 13 months, transplantation from a nonsibling donor, and any serological cytomegalovirus mismatch in donor-recipient pairs were significantly associated with severe acute GVHD and inferior EFS. The choice of busulfan- or treosulfan-based conditioning, type of GVHD prophylaxis, and serotherapy did not impact overall survival, EFS, or aGVHD. An intrinsic inflammatory component of LAD may contribute to inflammatory complications during allo-HSCT, thus providing the rationale for considering anti-inflammatory therapy pretreatment.

Published
2021

16. Correction: Myeloablative conditioning for allo-HSCT in pediatric ALL: FTBI or chemotherapy?—A multicenter EBMT-PDWP study (Bone Marrow Transplantation, (2020), 55, 8, (1540-1551), 10.1038/s41409-020-0854-0)

Author

Willasch, A. M., Peters, C., Sedlacek, P., Dalle, J. -H., Kitra-Roussou, V., Yesilipek, A., Wachowiak, J., Lankester, A., Prete, A., Hamidieh, A. A., Ifversen, M., Buechner, J., Krivan, G., Hamladji, R. -M., Diaz-de-Heredia, C., Skorobogatova, E., Michel, G., Locatelli, F., Bertaina, A., Veys, P., Dupont, S., Or, R., Gungor, T., Aleinikova, O., Sufliarska, S., Sundin, M., Rascon, J., Kaare, A., Nemet, D., Fagioli, F., Klingebiel, T. E., Styczynski, J., Bierings, M., Nagy, K., Abecasis, M., Afanasyev, B., Ansari, M., Vettenranta, K., Alseraihy, A., Chybicka, A., Robinson, S., Bertrand, Y., Kupesiz, A., Ghavamzadeh, A., Campos, A., Pichler, H., Dalissier, A., Labopin, M., Corbacioglu, S., Balduzzi, A., Galimard, J. -E., and Bader, P.

Subjects
Settore MED/38 - PEDIATRIA GENERALE E SPECIALISTICA, conditioning regimens
Published
2021

17. Geographical Distribution, Incidence, Malignancies, and Outcome of 136 Eastern Slavic Patients With Nijmegen Breakage Syndrome and NBN Founder Variant c.657_661del5

Author

Sharapova, S. O., Pashchenko, O. E., Bondarenko, A. V., Vakhlyarskaya, S. S., Prokofjeva, T., Fedorova, A. S., Savchak, I., Mareika, Y., Valiev, T. T., Popa, A., Tuzankina, I. A., Vlasova, E. V., Sakovich, I. S., Polyakova, E. A., Rumiantseva, N. V., Naumchik, I. V., Kulyova, S. A., Aleshkevich, S. N., Golovataya, E. I., Minakovskaya, N. V., Belevtsev, M. V., Latysheva, E. A., Latysheva, T. V., Beznoshchenko, A. G., Akopyan, H., Makukh, H., Kozlova, O., Varabyou, D. S., Ballow, M., Ong, M. -S., Walter, J. E., Kondratenko, I. V., Kostyuchenko, L. V., Aleinikova, O. V., Sharapova, S. O., Pashchenko, O. E., Bondarenko, A. V., Vakhlyarskaya, S. S., Prokofjeva, T., Fedorova, A. S., Savchak, I., Mareika, Y., Valiev, T. T., Popa, A., Tuzankina, I. A., Vlasova, E. V., Sakovich, I. S., Polyakova, E. A., Rumiantseva, N. V., Naumchik, I. V., Kulyova, S. A., Aleshkevich, S. N., Golovataya, E. I., Minakovskaya, N. V., Belevtsev, M. V., Latysheva, E. A., Latysheva, T. V., Beznoshchenko, A. G., Akopyan, H., Makukh, H., Kozlova, O., Varabyou, D. S., Ballow, M., Ong, M. -S., Walter, J. E., Kondratenko, I. V., Kostyuchenko, L. V., and Aleinikova, O. V.

Abstract

Nijmegen breakage syndrome (NBS) is a DNA repair disorder characterized by combined immunodeficiency and a high predisposition to lymphoid malignancies. The majority of NBS patients are identified with a homozygous five base pair deletion in the Nibrin (NBN) gene (c.657_661del5, p.K219fsX19) with a founder effect observed in Caucasian European populations, especially of Slavic origin. We present here an analysis of a cohort of 136 NBS patients of Eastern Slav origin across Belarus, Ukraine, Russia, and Latvia with a focus on understanding the geographic distribution, incidence of malignancy, and treatment outcomes of this cohort. Our analysis shows that Belarus had the highest prevalence of NBS (2.3 per 1,000,000), followed by Ukraine (1.3 per 1,000,000), and Russia (0.7 per 1,000,000). Of note, the highest concentration of NBS cases was observed in the western regions of Belarus and Ukraine, where NBS prevalence exceeds 20 cases per 1,000,000 people, suggesting the presence of an “Eastern Slavic NBS hot spot.” The median age at diagnosis of this cohort ranged from 4 to 5 years, and delay in diagnosis was more pervasive in smaller cities and rural regions. A total of 62 (45%) patients developed malignancies, more commonly in males than females (55.2 vs. 34.2%; p=0.017). In 27 patients, NBS was diagnosed following the onset of malignancies (mean age: 8 years). Malignancies were mostly of lymphoid origin and predominantly non-Hodgkin lymphoma (NHL) (n=42, 68%); 38% of patients had diffuse large B-cell lymphoma. The 20-year overall survival rate of patients with malignancy was 24%. However, females with cancer experienced poorer event-free survival rates than males (16.6% vs. 46.8%, p=0.036). Of 136 NBS patients, 13 underwent hematopoietic stem cell transplantation (HSCT) with an overall survival of 3.5 years following treatment (range: 1 to 14 years). Indications for HSCT included malignancy (n=7) and immunodeficiency (n=6). Overall, 9% of patients in this cohort reac

Published
2021

18. Total body irradiation or chemotherapy conditioning in childhood all: A multinational, randomized, noninferiority phase III study

Author

Peters, C., Dalle, J. -H., Locatelli, Franco, Poetschger, U., Sedlacek, P., Buechner, J., Shaw, P. J., Staciuk, R., Ifversen, M., Pichler, H., Vettenranta, K., Svec, P., Aleinikova, O., Stein, J., Gungor, T., Toporski, J., Truong, T. H., Diaz-De-Heredia, C., Bierings, M., Ariffin, H., Essa, M., Burkhardt, B., Schultz, K., Meisel, R., Lankester, A., Ansari, M., Schrappe, M., von Stackelberg, A., Balduzzi, A., Corbacioglu, S., Bader, P., Locatelli F. (ORCID:0000-0002-7976-3654), Peters, C., Dalle, J. -H., Locatelli, Franco, Poetschger, U., Sedlacek, P., Buechner, J., Shaw, P. J., Staciuk, R., Ifversen, M., Pichler, H., Vettenranta, K., Svec, P., Aleinikova, O., Stein, J., Gungor, T., Toporski, J., Truong, T. H., Diaz-De-Heredia, C., Bierings, M., Ariffin, H., Essa, M., Burkhardt, B., Schultz, K., Meisel, R., Lankester, A., Ansari, M., Schrappe, M., von Stackelberg, A., Balduzzi, A., Corbacioglu, S., Bader, P., and Locatelli F. (ORCID:0000-0002-7976-3654)

Abstract

PURPOSE Total body irradiation (TBI) before allogeneic hematopoietic stem cell transplantation (HSCT) in pediatric patients with acute lymphoblastic leukemia (ALL) is efficacious, but long-term side effects are concerning. We investigated whether preparative combination chemotherapy could replace TBI in such patients. PATIENTS AND METHODS FORUM is a randomized, controlled, open-label, international, multicenter, phase III, noninferiority study. Patients # 18 years at diagnosis, 4-21 years at HSCT, in complete remission pre-HSCT, and with an HLA-compatible related or unrelated donor were randomly assigned to myeloablative conditioning with fractionated 12 Gy TBI and etoposide versus fludarabine, thiotepa, and either busulfan or treosulfan. The noninferiority margin was 8%. With 1,000 patients randomly assigned in 5 years, 2-year minimum follow-up, and one-sided alpha of 5%, 80% power was calculated. A futility stopping rule would halt random assignment if chemoconditioning was significantly inferior to TBI (EudraCT: 2012-003032-22; ClinicalTrials.gov: NCT01949129). RESULTS Between April 2013 and December 2018, 543 patients were screened, 417 were randomly assigned, 212 received TBI, and 201 received chemoconditioning. The stopping rule was applied on March 31, 2019. The median follow-up was 2.1 years. In the intention-to-treat population, 2-year overall survival (OS) was significantly higher following TBI (0.91; 95% CI, 0.86 to 0.95; P,.0001) versus chemoconditioning (0.75; 95% CI, 0.67 to 0.81). Two-year cumulative incidence of relapse and treatment-related mortality were 0.12 (95% CI, 0.08 to 0.17; P,.0001) and 0.02 (95% CI,, 0.01 to 0.05; P 5.0269) following TBI and 0.33 (95% CI, 0.25 to 0.40) and 0.09 (95% CI, 0.05 to 0.14) following chemoconditioning, respectively. CONCLUSION Improved OS and lower relapse risk were observed following TBI plus etoposide compared with chemoconditioning. We therefore recommend TBI plus etoposide for patients. 4 years old with high

Published
2021

19. Total Body Irradiation or Chemotherapy Conditioning in Childhood ALL: A Multinational, Randomized, Noninferiority Phase III Study

Author

Peters, C, Dalle, J, Locatelli, F, Poetschger, U, Sedlacek, P, Buechner, J, Shaw, P, Staciuk, R, Ifversen, M, Pichler, H, Vettenranta, K, Svec, P, Aleinikova, O, Stein, J, Güngör, T, Toporski, J, Truong, T, Diaz-de-Heredia, C, Bierings, M, Ariffin, H, Essa, M, Burkhardt, B, Schultz, K, Meisel, R, Lankester, A, Ansari, M, Schrappe, M, von Stackelberg, A, Balduzzi, A, Corbacioglu, S, Bader, P, Peters, Christina, Dalle, Jean-Hugues, Locatelli, Franco, Poetschger, Ulrike, Sedlacek, Petr, Buechner, Jochen, Shaw, Peter J, Staciuk, Raquel, Ifversen, Marianne, Pichler, Herbert, Vettenranta, Kim, Svec, Peter, Aleinikova, Olga, Stein, Jerry, Güngör, Tayfun, Toporski, Jacek, Truong, Tony H, Diaz-de-Heredia, Cristina, Bierings, Marc, Ariffin, Hany, Essa, Mohammed, Burkhardt, Birgit, Schultz, Kirk, Meisel, Roland, Lankester, Arjan, Ansari, Marc, Schrappe, Martin, von Stackelberg, Arend, Balduzzi, Adriana, Corbacioglu, Selim, Bader, Peter, Peters, C, Dalle, J, Locatelli, F, Poetschger, U, Sedlacek, P, Buechner, J, Shaw, P, Staciuk, R, Ifversen, M, Pichler, H, Vettenranta, K, Svec, P, Aleinikova, O, Stein, J, Güngör, T, Toporski, J, Truong, T, Diaz-de-Heredia, C, Bierings, M, Ariffin, H, Essa, M, Burkhardt, B, Schultz, K, Meisel, R, Lankester, A, Ansari, M, Schrappe, M, von Stackelberg, A, Balduzzi, A, Corbacioglu, S, Bader, P, Peters, Christina, Dalle, Jean-Hugues, Locatelli, Franco, Poetschger, Ulrike, Sedlacek, Petr, Buechner, Jochen, Shaw, Peter J, Staciuk, Raquel, Ifversen, Marianne, Pichler, Herbert, Vettenranta, Kim, Svec, Peter, Aleinikova, Olga, Stein, Jerry, Güngör, Tayfun, Toporski, Jacek, Truong, Tony H, Diaz-de-Heredia, Cristina, Bierings, Marc, Ariffin, Hany, Essa, Mohammed, Burkhardt, Birgit, Schultz, Kirk, Meisel, Roland, Lankester, Arjan, Ansari, Marc, Schrappe, Martin, von Stackelberg, Arend, Balduzzi, Adriana, Corbacioglu, Selim, and Bader, Peter

Abstract

Purpose: Total body irradiation (TBI) before allogeneic hematopoietic stem cell transplantation (HSCT) in pediatric patients with acute lymphoblastic leukemia (ALL) is efficacious, but long-term side effects are concerning. We investigated whether preparative combination chemotherapy could replace TBI in such patients. Patients and methods: FORUM is a randomized, controlled, open-label, international, multicenter, phase III, noninferiority study. Patients ≤ 18 years at diagnosis, 4-21 years at HSCT, in complete remission pre-HSCT, and with an HLA-compatible related or unrelated donor were randomly assigned to myeloablative conditioning with fractionated 12 Gy TBI and etoposide versus fludarabine, thiotepa, and either busulfan or treosulfan. The noninferiority margin was 8%. With 1,000 patients randomly assigned in 5 years, 2-year minimum follow-up, and one-sided alpha of 5%, 80% power was calculated. A futility stopping rule would halt random assignment if chemoconditioning was significantly inferior to TBI (EudraCT: 2012-003032-22; ClinicalTrials.gov: NCT01949129). Results: Between April 2013 and December 2018, 543 patients were screened, 417 were randomly assigned, 212 received TBI, and 201 received chemoconditioning. The stopping rule was applied on March 31, 2019. The median follow-up was 2.1 years. In the intention-to-treat population, 2-year overall survival (OS) was significantly higher following TBI (0.91; 95% CI, 0.86 to 0.95; P < .0001) versus chemoconditioning (0.75; 95% CI, 0.67 to 0.81). Two-year cumulative incidence of relapse and treatment-related mortality were 0.12 (95% CI, 0.08 to 0.17; P < .0001) and 0.02 (95% CI, < 0.01 to 0.05; P = .0269) following TBI and 0.33 (95% CI, 0.25 to 0.40) and 0.09 (95% CI, 0.05 to 0.14) following chemoconditioning, respectively. Conclusion: Improved OS and lower relapse risk were observed following TBI plus etoposide compared with chemoconditioning. We therefore recommend TBI plus etoposide for patients >

Published
2021

21. Prognostic significance of various 11q23/KMT2A rearrangements in infants with acute lymphoblastic leuekemia

Author

Tsaur, G. A., primary, Riger, T. O., additional, Popov, A. M., additional, Kustanovich, A. M., additional, Olshanskaya, Yu. V., additional, Nasedkina, T. V., additional, Solodovnikov, A. G., additional, Shorikov, E. V., additional, Demina, A. S., additional, Plekhanova, O. M., additional, Nokhrina, E. S., additional, Verzhbitskaya, T. Yu., additional, Streneva, O. V., additional, Makarova, O. V., additional, Arakaev, O. R., additional, Seveliev, L. I., additional, Aleinikova, O. V., additional, Lapotentova, E. S., additional, Myakova, N. V., additional, Fominykh, V. V., additional, Kondratchik, K. L., additional, Boichenko, E. G., additional, Ponomareva, N. I., additional, Karachunskiy, A. I., additional, Roumiantsev, A. G., additional, and Fechina, L. G., additional

Published
2021
Full Text
View/download PDF

24. The MLL recombinome of acute leukemias in 2013

Author

Meyer, C, Hofmann, J, Burmeister, T, Gröger, D, Park, T S, Emerenciano, M, Pombo de Oliveira, M, Renneville, A, Villarese, P, Macintyre, E, Cavé, H, Clappier, E, Mass-Malo, K, Zuna, J, Trka, J, De Braekeleer, E, De Braekeleer, M, Oh, S H, Tsaur, G, Fechina, L, van der Velden, V HJ, van Dongen, J JM, Delabesse, E, Binato, R, Silva, M LM, Kustanovich, A, Aleinikova, O, Harris, M H, Lund-Aho, T, Juvonen, V, Heidenreich, O, Vormoor, J, Choi, W WL, Jarosova, M, Kolenova, A, Bueno, C, Menendez, P, Wehner, S, Eckert, C, Talmant, P, Tondeur, S, Lippert, E, Launay, E, Henry, C, Ballerini, P, Lapillone, H, Callanan, M B, Cayuela, J M, Herbaux, C, Cazzaniga, G, Kakadiya, P M, Bohlander, S, Ahlmann, M, Choi, J R, Gameiro, P, Lee, D S, Krauter, J, Cornillet-Lefebvre, P, Te Kronnie, G, Schäfer, B W, Kubetzko, S, Alonso, C N, zur Stadt, U, Sutton, R, Venn, N C, Izraeli, S, Trakhtenbrot, L, Madsen, H O, Archer, P, Hancock, J, Cerveira, N, Teixeira, M R, Lo Nigro, L, Möricke, A, Stanulla, M, Schrappe, M, Sedék, L, Szczepański, T, Zwaan, C M, Coenen, E A, van den Heuvel-Eibrink, M M, Strehl, S, Dworzak, M, Panzer-Grümayer, R, Dingermann, T, Klingebiel, T, and Marschalek, R

Published
2013
Full Text
View/download PDF

25. The MLL recombinome of acute leukemias in 2017

Author

Meyer, C, Burmeister, T, Gröger, D, Tsaur, G, Fechina, L, Renneville, A, Sutton, R, Venn, N, Emerenciano, M, Pombo-De-Oliveira, M, Barbieri Blunck, C, Almeida Lopes, B, Zuna, J, Trka, J, Ballerini, P, Lapillonne, H, De Braekeleer, M, Cazzaniga, G, Corral Abascal, L, Van Der Velden, V, Delabesse, E, Park, T, Oh, S, Silva, M, Lund-Aho, T, Juvonen, V, Moore, A, Heidenreich, O, Vormoor, J, Zerkalenkova, E, Olshanskaya, Y, Bueno, C, Menendez, P, Teigler-Schlegel, A, Zur Stadt, U, Lentes, J, Göhring, G, Kustanovich, A, Aleinikova, O, Schäfer, B, Kubetzko, S, Madsen, H, Gruhn, B, Duarte, X, Gameiro, P, Lippert, E, Bidet, A, Cayuela, J, Clappier, E, Alonso, C, Zwaan, C, Van Den Heuvel-Eibrink, M, Izraeli, S, Trakhtenbrot, L, Archer, P, Hancock, J, Möricke, A, Alten, J, Schrappe, M, Stanulla, M, Strehl, S, Attarbaschi, A, Dworzak, M, Haas, O, Panzer-Grümayer, R, Sedék, L, Szczepa, T, Caye, A, Suarez, L, Cavé, H, Marschalek, R, Meyer, C., Burmeister, T., Gröger, D., Tsaur, G., Fechina, L., Renneville, A., Sutton, R., Venn, N. C., Emerenciano, M., Pombo-De-Oliveira, M. S., Barbieri Blunck, C., Almeida Lopes, B., Zuna, J., Trka, J., Ballerini, P., Lapillonne, H., De Braekeleer, M., Cazzaniga, G., Corral Abascal, L., Van Der Velden, V. H. J., Delabesse, E., Park, T. S., Oh, S. H., Silva, M. L. M., Lund-Aho, T., Juvonen, V., Moore, A. S., Heidenreich, O., Vormoor, J., Zerkalenkova, E., Olshanskaya, Y., Bueno, C., Menendez, P., Teigler-Schlegel, A., Zur Stadt, U., Lentes, J., Göhring, G., Kustanovich, A., Aleinikova, O., Schäfer, B. W., Kubetzko, S., Madsen, H. O., Gruhn, B., Duarte, X., Gameiro, P., Lippert, E., Bidet, A., Cayuela, J. M., Clappier, E., Alonso, C. N., Zwaan, C. M., Van Den Heuvel-Eibrink, M. M., Izraeli, S., Trakhtenbrot, L., Archer, P., Hancock, J., Möricke, A., Alten, J., Schrappe, M., Stanulla, M., Strehl, S., Attarbaschi, A., Dworzak, M., Haas, O. A., Panzer-Grümayer, R., Sedék, L., Szczepa, T., Caye, A., Suarez, L., Cavé, H., Marschalek, R., Meyer, C, Burmeister, T, Gröger, D, Tsaur, G, Fechina, L, Renneville, A, Sutton, R, Venn, N, Emerenciano, M, Pombo-De-Oliveira, M, Barbieri Blunck, C, Almeida Lopes, B, Zuna, J, Trka, J, Ballerini, P, Lapillonne, H, De Braekeleer, M, Cazzaniga, G, Corral Abascal, L, Van Der Velden, V, Delabesse, E, Park, T, Oh, S, Silva, M, Lund-Aho, T, Juvonen, V, Moore, A, Heidenreich, O, Vormoor, J, Zerkalenkova, E, Olshanskaya, Y, Bueno, C, Menendez, P, Teigler-Schlegel, A, Zur Stadt, U, Lentes, J, Göhring, G, Kustanovich, A, Aleinikova, O, Schäfer, B, Kubetzko, S, Madsen, H, Gruhn, B, Duarte, X, Gameiro, P, Lippert, E, Bidet, A, Cayuela, J, Clappier, E, Alonso, C, Zwaan, C, Van Den Heuvel-Eibrink, M, Izraeli, S, Trakhtenbrot, L, Archer, P, Hancock, J, Möricke, A, Alten, J, Schrappe, M, Stanulla, M, Strehl, S, Attarbaschi, A, Dworzak, M, Haas, O, Panzer-Grümayer, R, Sedék, L, Szczepa, T, Caye, A, Suarez, L, Cavé, H, Marschalek, R, Meyer, C., Burmeister, T., Gröger, D., Tsaur, G., Fechina, L., Renneville, A., Sutton, R., Venn, N. C., Emerenciano, M., Pombo-De-Oliveira, M. S., Barbieri Blunck, C., Almeida Lopes, B., Zuna, J., Trka, J., Ballerini, P., Lapillonne, H., De Braekeleer, M., Cazzaniga, G., Corral Abascal, L., Van Der Velden, V. H. J., Delabesse, E., Park, T. S., Oh, S. H., Silva, M. L. M., Lund-Aho, T., Juvonen, V., Moore, A. S., Heidenreich, O., Vormoor, J., Zerkalenkova, E., Olshanskaya, Y., Bueno, C., Menendez, P., Teigler-Schlegel, A., Zur Stadt, U., Lentes, J., Göhring, G., Kustanovich, A., Aleinikova, O., Schäfer, B. W., Kubetzko, S., Madsen, H. O., Gruhn, B., Duarte, X., Gameiro, P., Lippert, E., Bidet, A., Cayuela, J. M., Clappier, E., Alonso, C. N., Zwaan, C. M., Van Den Heuvel-Eibrink, M. M., Izraeli, S., Trakhtenbrot, L., Archer, P., Hancock, J., Möricke, A., Alten, J., Schrappe, M., Stanulla, M., Strehl, S., Attarbaschi, A., Dworzak, M., Haas, O. A., Panzer-Grümayer, R., Sedék, L., Szczepa, T., Caye, A., Suarez, L., Cavé, H., and Marschalek, R.

Abstract

Chromosomal rearrangements of the human MLL/KMT2A gene are associated with infant, pediatric, adult and therapy-induced acute leukemias. Here we present the data obtained from 2345 acute leukemia patients. Genomic breakpoints within the MLL gene and the involved translocation partner genes (TPGs) were determined and 11 novel TPGs were identified. Thus, a total of 135 different MLL rearrangements have been identified so far, of which 94 TPGs are now characterized at the molecular level. In all, 35 out of these 94 TPGs occur recurrently, but only 9 specific gene fusions account for more than 90% of all illegitimate recombinations of the MLL gene. We observed an age-dependent breakpoint shift with breakpoints localizing within MLL intron 11 associated with acute lymphoblastic leukemia and younger patients, while breakpoints in MLL intron 9 predominate in AML or older patients. The molecular characterization of MLL breakpoints suggests different etiologies in the different age groups and allows the correlation of functional domains of the MLL gene with clinical outcome. This study provides a comprehensive analysis of the MLL recombinome in acute leukemia and demonstrates that the establishment of patient-specific chromosomal fusion sites allows the design of specific PCR primers for minimal residual disease analyses for all patients

Published
2018

27. The Clinical and Genetic Spectrum of 82 Patients With RAG Deficiency Including a c.256_257delAA Founder Variant in Slavic Countries

Author

Sharapova, S.O. (Svetlana O.), Skomska-Pawliszak, M. (Małgorzata), Rodina, Y.A. (Yulia A.), Wolska-Kusnierz, B. (Beata), Dabrowska-Leonik, N. (Nel), Mikoluc, B. (Bozena), Pashchenko, O.E. (Olga E.), Pasic, S. (Srdjan), Freiberger, T. (Tomáš), Milota, T. (Tomáš), Formánková, R. (Renata), Szaflarska, A. (Anna), Siedlar, M. (Maciej), Avcin, T. (Tadej), Markelj, G. (Gašper), Ciznar, P. (P.), Kalwak, K. (Krzysztof), Kołtan, S. (Sylwia), Jackowska, T. (Teresa), Drabko, K. (Katarzyna), Gagro, A. (Alenka), Pac, M. (Malgorzata), Naumova, E. (Elissaveta), Kandilarova, S. (Snezhina), Babol-Pokora, K. (Katarzyna), Varabyou, D.S. (Dzmitry S.), Barendregt, B.H. (Barbara), Raykina, E.V. (Elena V.), Varlamova, T.V. (Tatiana V.), Pavlova, A.V. (Anna V.), Grombirikova, H. (Hana), Debeljak, M. (Maruša), Mersiyanova, I.V. (Irina V.), Bondarenko, A.V. (Anastasiia V.), Chernyshova, L.I. (Liudmyla I.), Kostyuchenko, L. (Larysa), Guseva, M. (Marina), Rascon, J. (Jelena), Muleviciene, A. (Audrone), Preiksaitiene, E. (Egle), Geier, C.B. (Christoph B.), Leiss-Piller, A. (Alexander), Yamazaki, Y. (Yasuhiro), Kawai, T. (Tomoki), Walter, J.E. (Jolan E.), Kondratenko, I. (Irina), Sediva, A. (A.), Burg, M. (Mirjam) van der, Kuzmenko, N.B. (Natalia B.), Notarangelo, L.D. (Luigi Daniele), Bernatowska, E. (Ewa), Aleinikova, O. (O.), Sharapova, S.O. (Svetlana O.), Skomska-Pawliszak, M. (Małgorzata), Rodina, Y.A. (Yulia A.), Wolska-Kusnierz, B. (Beata), Dabrowska-Leonik, N. (Nel), Mikoluc, B. (Bozena), Pashchenko, O.E. (Olga E.), Pasic, S. (Srdjan), Freiberger, T. (Tomáš), Milota, T. (Tomáš), Formánková, R. (Renata), Szaflarska, A. (Anna), Siedlar, M. (Maciej), Avcin, T. (Tadej), Markelj, G. (Gašper), Ciznar, P. (P.), Kalwak, K. (Krzysztof), Kołtan, S. (Sylwia), Jackowska, T. (Teresa), Drabko, K. (Katarzyna), Gagro, A. (Alenka), Pac, M. (Malgorzata), Naumova, E. (Elissaveta), Kandilarova, S. (Snezhina), Babol-Pokora, K. (Katarzyna), Varabyou, D.S. (Dzmitry S.), Barendregt, B.H. (Barbara), Raykina, E.V. (Elena V.), Varlamova, T.V. (Tatiana V.), Pavlova, A.V. (Anna V.), Grombirikova, H. (Hana), Debeljak, M. (Maruša), Mersiyanova, I.V. (Irina V.), Bondarenko, A.V. (Anastasiia V.), Chernyshova, L.I. (Liudmyla I.), Kostyuchenko, L. (Larysa), Guseva, M. (Marina), Rascon, J. (Jelena), Muleviciene, A. (Audrone), Preiksaitiene, E. (Egle), Geier, C.B. (Christoph B.), Leiss-Piller, A. (Alexander), Yamazaki, Y. (Yasuhiro), Kawai, T. (Tomoki), Walter, J.E. (Jolan E.), Kondratenko, I. (Irina), Sediva, A. (A.), Burg, M. (Mirjam) van der, Kuzmenko, N.B. (Natalia B.), Notarangelo, L.D. (Luigi Daniele), Bernatowska, E. (Ewa), and Aleinikova, O. (O.)

Abstract

Background: Variants in recombination-activating genes (RAG) are common genetic causes of autosomal recessive forms of combined immunodeficiencies (CID) ranging from severe combined immunodeficiency (SCID), Omenn syndrome (OS), leaky SCID, and CID with granulomas and/or autoimmunity (CID-G/AI), and even milder presentation with antibody deficiency. Objective: We aim to estimate the incidence, clinical presentation, genetic variability, and treatment outcome with geographic distribution of patients with the RAG defects in populations inhabiting South, West, and East Slavic countries. Methods: Demographic, clinical, and laboratory data were collected from RAG-deficient patients of Slavic origin via chart review, retrospectively. Recombinase activity was determined in vitro by flow cytometry-based assay. Results: Based on the clinical and immunologic phenotype, our cohort of 82 patients from 68 families represented a wide spectrum of RAG deficiencies, including SCID (n = 20), OS (n = 37), and LS/CID (n = 25) phenotypes. Sixty-seven (81.7%) patients carried RAG1 and 15 patients (18.3%) carried RAG2 biallelic variants. We estimate that the minimal annual incidence of RAG deficiency in Slavic countries varies between 1 in 180,000 and 1 in 300,000 live births, and it may vary secondary to health care disparities in these regions. In our cohort, 70% (n = 47) of patients with RAG1 variants carried p.K86Vfs*33 (c.256_257delAA) allele, either in homozygous (n = 18, 27%) or in compound heterozygous (n = 29, 43%) form. The majority (77%) of patients with homozygous RAG1 p.K86Vfs*33 variant originated from Vistula watershed area in Central and Eastern Poland, and compound heterozygote cases were distributed among all Slavic countries except Bulgaria. Clinical and immunological presentation of homozygous RAG1 p.K86Vfs*33 cases was highly diverse (SCID, OS, and AS/CID) suggestive of strong influence of additional genetic and/or epigenetic factors in shaping the final phenotype. Con

Published
2020
Full Text
View/download PDF

28. Prognostic value of minimal residual disease measured by flow-cytometry in two cohorts of infants with acute lymphoblastic leukemia treated according to either MLL-Baby or Interfant protocols

Author

Popov, A., Buldini, B., De Lorenzo, P., Disaro, S., Verzhbitskaya, T., Movchan, L., Giarin, E., Shorikov, E., Di Meglio, A., Tsaur, G., Parasole, R., Miakova, N., Boichenko, E., Kondratchik, K., Aleinikova, O., Karachunskiy, A., Roumiantsev, A., Locatelli, Franco, Biondi, A., Pieters, R., Valsecchi, M. G., Fechina, L., Basso, G., Locatelli F. (ORCID:0000-0002-7976-3654), Popov, A., Buldini, B., De Lorenzo, P., Disaro, S., Verzhbitskaya, T., Movchan, L., Giarin, E., Shorikov, E., Di Meglio, A., Tsaur, G., Parasole, R., Miakova, N., Boichenko, E., Kondratchik, K., Aleinikova, O., Karachunskiy, A., Roumiantsev, A., Locatelli, Franco, Biondi, A., Pieters, R., Valsecchi, M. G., Fechina, L., Basso, G., and Locatelli F. (ORCID:0000-0002-7976-3654)

Abstract

NO ABSTRACT

Published
2020

29. Myeloablative conditioning for allo-HSCT in pediatric ALL: FTBI or chemotherapy?—A multicenter EBMT-PDWP study

Author

Willasch, A. M., Peters, C., Sedlacek, P., Dalle, J. -H., Kitra-Roussou, V., Yesilipek, A., Wachowiak, J., Lankester, A., Prete, A., Hamidieh, A. A., Ifversen, M., Buechner, J., Krivan, G., Hamladji, R. -M., Diaz-de-Heredia, C., Skorobogatova, E., Michel, G., Locatelli, Franco, Bertaina, A., Veys, P., Dupont, S., Or, R., Gungor, T., Aleinikova, O., Sufliarska, S., Sundin, M., Rascon, J., Kaare, A., Nemet, D., Fagioli, F., Klingebiel, T. E., Styczynski, J., Bierings, M., Nagy, K., Abecasis, M., Afanasyev, B., Ansari, M., Vettenranta, K., Alseraihy, A., Chybicka, A., Robinson, S., Bertrand, Y., Kupesiz, A., Ghavamzadeh, A., Campos, A., Pichler, H., Dalissier, A., Labopin, M., Corbacioglu, S., Balduzzi, A., Galimard, J. -E., Bader, P., Locatelli F. (ORCID:0000-0002-7976-3654), Willasch, A. M., Peters, C., Sedlacek, P., Dalle, J. -H., Kitra-Roussou, V., Yesilipek, A., Wachowiak, J., Lankester, A., Prete, A., Hamidieh, A. A., Ifversen, M., Buechner, J., Krivan, G., Hamladji, R. -M., Diaz-de-Heredia, C., Skorobogatova, E., Michel, G., Locatelli, Franco, Bertaina, A., Veys, P., Dupont, S., Or, R., Gungor, T., Aleinikova, O., Sufliarska, S., Sundin, M., Rascon, J., Kaare, A., Nemet, D., Fagioli, F., Klingebiel, T. E., Styczynski, J., Bierings, M., Nagy, K., Abecasis, M., Afanasyev, B., Ansari, M., Vettenranta, K., Alseraihy, A., Chybicka, A., Robinson, S., Bertrand, Y., Kupesiz, A., Ghavamzadeh, A., Campos, A., Pichler, H., Dalissier, A., Labopin, M., Corbacioglu, S., Balduzzi, A., Galimard, J. -E., Bader, P., and Locatelli F. (ORCID:0000-0002-7976-3654)

Abstract

Although most children with acute lymphoblastic leukemia (ALL) receive fractionated total body irradiation (FTBI) as myeloablative conditioning (MAC) for allogeneic hematopoietic stem cell transplantation (allo-HSCT), it is an important matter of debate if chemotherapy can effectively replace FTBI. To compare outcomes after FTBI versus chemotherapy-based conditioning (CC), we performed a retrospective EBMT registry study. Children aged 2–18 years after MAC for first allo-HSCT of bone marrow (BM) or peripheral blood stem cells (PBSC) from matched-related (MRD) or unrelated donors (UD) in first (CR1) or second remission (CR2) between 2000 and 2012 were included. Propensity score weighting was used to control pretreatment imbalances of the observed variables. 3.054 patients were analyzed. CR1 (1.498): median follow-up (FU) after FTBI (1.285) and CC (213) was 6.8 and 6.1 years. Survivals were not significantly different. CR2 (1.556): median FU after FTBI (1.345) and CC (211) was 6.2 years. Outcomes after FTBI were superior as compared with CC with regard to overall survival (OS), leukemia-free survival (LFS), relapse incidence (RI), and nonrelapse mortality (NRM). However, we must emphasize the preliminary character of the results of this retrospective “real-world-practice” study. These findings will be prospectively assessed in the ALL SCTped 2012 FORUM trial.

Published
2020

30. Myeloablative conditioning for allo-HSCT in pediatric ALL: FTBI or chemotherapy?—A multicenter EBMT-PDWP study

Author

Willasch, A, Peters, C, Sedláček, P, Dalle, J, Kitra-Roussou, V, Yesilipek, A, Wachowiak, J, Lankester, A, Prete, A, Hamidieh, A, Ifversen, M, Buechner, J, Kriván, G, Hamladji, R, Diaz-de-Heredia, C, Skorobogatova, E, Michel, G, Locatelli, F, Bertaina, A, Veys, P, Dupont, S, Or, R, Güngör, T, Aleinikova, O, Sufliarska, S, Sundin, M, Rascon, J, Kaare, A, Nemet, D, Fagioli, F, Klingebiel, T, Styczynski, J, Bierings, M, Nagy, K, Abecasis, M, Afanasyev, B, Ansari, M, Vettenranta, K, Alseraihy, A, Chybicka, A, Robinson, S, Bertrand, Y, Kupesiz, A, Ghavamzadeh, A, Campos, A, Pichler, H, Dalissier, A, Labopin, M, Corbacioglu, S, Balduzzi, A, Galimard, J, Bader, P, Willasch, Andre Manfred, Peters, Christina, Sedláček, Petr, Dalle, Jean-Hugues, Kitra-Roussou, Vassiliki, Yesilipek, Akif, Wachowiak, Jacek, Lankester, Arjan, Prete, Arcangelo, Hamidieh, Amir Ali, Ifversen, Marianne, Buechner, Jochen, Kriván, Gergely, Hamladji, Rose-Marie, Diaz-de-Heredia, Cristina, Skorobogatova, Elena, Michel, Gérard, Locatelli, Franco, Bertaina, Alice, Veys, Paul, Dupont, Sophie, Or, Reuven, Güngör, Tayfun, Aleinikova, Olga, Sufliarska, Sabina, Sundin, Mikael, Rascon, Jelena, Kaare, Ain, Nemet, Damir, Fagioli, Franca, Klingebiel, Thomas Erich, Styczynski, Jan, Bierings, Marc, Nagy, Kálmán, Abecasis, Manuel, Afanasyev, Boris, Ansari, Marc, Vettenranta, Kim, Alseraihy, Amal, Chybicka, Alicja, Robinson, Stephen, Bertrand, Yves, Kupesiz, Alphan, Ghavamzadeh, Ardeshir, Campos, Antonio, Pichler, Herbert, Dalissier, Arnaud, Labopin, Myriam, Corbacioglu, Selim, Balduzzi, Adriana, Galimard, Jacques-Emmanuel, Bader, Peter, Willasch, A, Peters, C, Sedláček, P, Dalle, J, Kitra-Roussou, V, Yesilipek, A, Wachowiak, J, Lankester, A, Prete, A, Hamidieh, A, Ifversen, M, Buechner, J, Kriván, G, Hamladji, R, Diaz-de-Heredia, C, Skorobogatova, E, Michel, G, Locatelli, F, Bertaina, A, Veys, P, Dupont, S, Or, R, Güngör, T, Aleinikova, O, Sufliarska, S, Sundin, M, Rascon, J, Kaare, A, Nemet, D, Fagioli, F, Klingebiel, T, Styczynski, J, Bierings, M, Nagy, K, Abecasis, M, Afanasyev, B, Ansari, M, Vettenranta, K, Alseraihy, A, Chybicka, A, Robinson, S, Bertrand, Y, Kupesiz, A, Ghavamzadeh, A, Campos, A, Pichler, H, Dalissier, A, Labopin, M, Corbacioglu, S, Balduzzi, A, Galimard, J, Bader, P, Willasch, Andre Manfred, Peters, Christina, Sedláček, Petr, Dalle, Jean-Hugues, Kitra-Roussou, Vassiliki, Yesilipek, Akif, Wachowiak, Jacek, Lankester, Arjan, Prete, Arcangelo, Hamidieh, Amir Ali, Ifversen, Marianne, Buechner, Jochen, Kriván, Gergely, Hamladji, Rose-Marie, Diaz-de-Heredia, Cristina, Skorobogatova, Elena, Michel, Gérard, Locatelli, Franco, Bertaina, Alice, Veys, Paul, Dupont, Sophie, Or, Reuven, Güngör, Tayfun, Aleinikova, Olga, Sufliarska, Sabina, Sundin, Mikael, Rascon, Jelena, Kaare, Ain, Nemet, Damir, Fagioli, Franca, Klingebiel, Thomas Erich, Styczynski, Jan, Bierings, Marc, Nagy, Kálmán, Abecasis, Manuel, Afanasyev, Boris, Ansari, Marc, Vettenranta, Kim, Alseraihy, Amal, Chybicka, Alicja, Robinson, Stephen, Bertrand, Yves, Kupesiz, Alphan, Ghavamzadeh, Ardeshir, Campos, Antonio, Pichler, Herbert, Dalissier, Arnaud, Labopin, Myriam, Corbacioglu, Selim, Balduzzi, Adriana, Galimard, Jacques-Emmanuel, and Bader, Peter

Abstract

Although most children with acute lymphoblastic leukemia (ALL) receive fractionated total body irradiation (FTBI) as myeloablative conditioning (MAC) for allogeneic hematopoietic stem cell transplantation (allo-HSCT), it is an important matter of debate if chemotherapy can effectively replace FTBI. To compare outcomes after FTBI versus chemotherapy-based conditioning (CC), we performed a retrospective EBMT registry study. Children aged 2-18 years after MAC for first allo-HSCT of bone marrow (BM) or peripheral blood stem cells (PBSC) from matched-related (MRD) or unrelated donors (UD) in first (CR1) or second remission (CR2) between 2000 and 2012 were included. Propensity score weighting was used to control pretreatment imbalances of the observed variables. 3.054 patients were analyzed. CR1 (1.498): median follow-up (FU) after FTBI (1.285) and CC (213) was 6.8 and 6.1 years. Survivals were not significantly different. CR2 (1.556): median FU after FTBI (1.345) and CC (211) was 6.2 years. Outcomes after FTBI were superior as compared with CC with regard to overall survival (OS), leukemia-free survival (LFS), relapse incidence (RI), and nonrelapse mortality (NRM). However, we must emphasize the preliminary character of the results of this retrospective "real-world-practice" study. These findings will be prospectively assessed in the ALL SCTped 2012 FORUM trial.

Published
2020

39. Disease evolution and response to rapamycin in Activated Phosphoinositide 3-Kinase delta syndrome: the european society for immunodeficiencies-Activated Phosphoinositide 3-Kinase d syndrome registry

Author

Maccari, M.E., Abolhassani, H., Aghamohammadi, A., Aiuti, A., Aleinikova, O., Bangs, C., Baris, S., Barzaghi, F., Baxendale, H., Buckland, M., Burns, S.O., Cancrini, C., Cant, A., Cathebras, P., Cavazzana, M., Chandra, A., Conti, F., Coulter, T., Devlin, L.A., Edgar, J.D.M., Faust, S., Fischer, A., Prat, M.G., Hammarstrom, L., Heeg, M., Jolles, S., Karakoc-Aydiner, E., Kindle, G., Kiykim, A., Kumararatne, D., Grimbacher, B., Longhurst, H., Mahlaoui, N., Milota, T., Moreira, F., Moshous, D., Mukhina, A., Neth, O., Neven, B., Nieters, A., Olbrich, P., Ozen, A., Schmid, J.P., Picard, C., Prader, S., Rae, W., Reichenbach, J., Rusch, S., Savic, S., Scarselli, A., Scheible, R., Sediva, A., Sharapova, S.O., Shcherbina, A., Slatter, M., Soler-Palacin, P., Stanislas, A., Suarez, F., Tucci, F., Uhlmann, A., van Montfrans, J., Warnatz, K., Williams, A.P., Wood, P., Kracker, S., Condliffe, A.M., and Ehl, S.

Abstract

Activated phosphoinositide 3-kinase (PI3K) δ Syndrome (APDS), caused by autosomal\ud dominant mutations in PIK3CD (APDS1) or PIK3R1 (APDS2), is a heterogeneous primary\ud immunodeficiency. While initial cohort-descriptions summarized the spectrum of clinical\ud and immunological manifestations, questions about long-term disease evolution and\ud response to therapy remain. The prospective European Society for Immunodeficiencies\ud (ESID)-APDS registry aims to characterize the disease course, identify outcome predictors,\ud and evaluate treatment responses. So far, 77 patients have been recruited (51\ud APDS1, 26 APDS2). Analysis of disease evolution in the first 68 patients pinpoints the early\ud occurrence of recurrent respiratory infections followed by chronic lymphoproliferation,\ud gastrointestinal manifestations, and cytopenias. Although most manifestations occur by\ud age 15, adult-onset and asymptomatic courses were documented. Bronchiectasis was\ud observed in 24/40 APDS1 patients who received a CT-scan compared with 4/15 APDS2\ud patients. By age 20, half of the patients had received at least one immunosuppressant,\ud but 2–3 lines of immunosuppressive therapy were not unusual before age 10. Response\ud to rapamycin was rated by physician visual analog scale as good in 10, moderate in 9,\ud and poor in 7. Lymphoproliferation showed the best response (8 complete, 11 partial,\ud 6 no remission), while bowel inflammation (3 complete, 3 partial, 9 no remission) and\ud cytopenia (3 complete, 2 partial, 9 no remission) responded less well. Hence, non-lymphoproliferative\ud manifestations should be a key target for novel therapies. This report from\ud the ESID-APDS registry provides comprehensive baseline documentation for a growing\ud cohort that will be followed prospectively to establish prognostic factors and identify\ud patients for treatment studies.

Published
2018

40. Mind maps as tools for expanding EFL students’ vocabulary

Author

Aleinikova, O. and Atajanov, A.

Subjects
English language, mind maps, vocabulary
Abstract

The Youth of the 21st Century: Education, Science, Innovations : Proceedings of V International Conference for Students, Postgraduates and Young Scientists, Vitebsk, December 12, 2018. - Vitebsk : Vitebsk State University named after P. M. Masherov , 2018. - P. 139-141. - Bibliogr.: p. 141 (2 nam.).

Published
2018

43. The MLL recombinome of acute leukemias in 2017

Author

Meyer, C., Burmeister, T., Gröger, D. (D.), Tsaur, G., Fechina, L., Renneville, A., Sutton, R., Venn, N., Emerenciano, M. (M.), Pombo-De-Oliveira, M.S. (M. S.), Barbieri Blunck, C. (C.), Almeida Lopes, B. (B.), Zuna, J., Trka, J. (Jan), Ballerini, P. (P.), Lapillonne, H. (H.), Braekeleer, E. de, Cazzaniga, G. (Gianni), Corral Abascal, L. (L.), Velden, V.H.J. (Vincent) van der, Delabesse, E., Park, T.S. (T. S.), Oh, S.H. (S.), Silva, M.L.M. (M. L M), Lund-Aho, T. (T.), Juvonen, V. (V.), Moore, A.S. (A.), Heidenreich, O., Vormoor, J. (J.), Zerkalenkova, E. (E.), Olshanskaya, Y. (Y.), Bueno, C. (C.), Menéndez, P. (Pablo), Teigler-Schlegel, A., zur Stadt, U., Lentes, J. (J.), Göhring, G. (Gudrun), Kustanovich, A. (A.), Aleinikova, O. (O.), Schäfer, B.W. (B. W.), Kubetzko, S. (S.), Madsen, H.O., Gruhn, B. (B.), Duarte, X. (X.), Gameiro, P., Lippert, E. (Eric), Bidet, A. (A.), Cayuela, J.-M. (Jean-Michel), Clappier, E., Alonso, C.N. (Cristina), Zwaan, C.M. (Michel), Heuvel-Eibrink, M.M. (Marry) van den, Izraeli, S. (Shai), Trakhtenbrot, L., Archer, P. (P.), Hancock, J., Möricke, A., Alten, J. (J.), Schrappe, M. (Martin), Stanulla, M. (Martin), Strehl, S., Attarbaschi, A. (Andishe), Dworzak, M.N. (Michael), Haas, O.A. (O. A.), Panzer-Grümayer, R. (Renate), Sedek, L. (Lukasz), Szczepa, T. (T.), Caye, A. (Aurélie), Suarez, L. (L.), Cavé, H. (Helene), Marschalek, R. (Rolf), Meyer, C., Burmeister, T., Gröger, D. (D.), Tsaur, G., Fechina, L., Renneville, A., Sutton, R., Venn, N., Emerenciano, M. (M.), Pombo-De-Oliveira, M.S. (M. S.), Barbieri Blunck, C. (C.), Almeida Lopes, B. (B.), Zuna, J., Trka, J. (Jan), Ballerini, P. (P.), Lapillonne, H. (H.), Braekeleer, E. de, Cazzaniga, G. (Gianni), Corral Abascal, L. (L.), Velden, V.H.J. (Vincent) van der, Delabesse, E., Park, T.S. (T. S.), Oh, S.H. (S.), Silva, M.L.M. (M. L M), Lund-Aho, T. (T.), Juvonen, V. (V.), Moore, A.S. (A.), Heidenreich, O., Vormoor, J. (J.), Zerkalenkova, E. (E.), Olshanskaya, Y. (Y.), Bueno, C. (C.), Menéndez, P. (Pablo), Teigler-Schlegel, A., zur Stadt, U., Lentes, J. (J.), Göhring, G. (Gudrun), Kustanovich, A. (A.), Aleinikova, O. (O.), Schäfer, B.W. (B. W.), Kubetzko, S. (S.), Madsen, H.O., Gruhn, B. (B.), Duarte, X. (X.), Gameiro, P., Lippert, E. (Eric), Bidet, A. (A.), Cayuela, J.-M. (Jean-Michel), Clappier, E., Alonso, C.N. (Cristina), Zwaan, C.M. (Michel), Heuvel-Eibrink, M.M. (Marry) van den, Izraeli, S. (Shai), Trakhtenbrot, L., Archer, P. (P.), Hancock, J., Möricke, A., Alten, J. (J.), Schrappe, M. (Martin), Stanulla, M. (Martin), Strehl, S., Attarbaschi, A. (Andishe), Dworzak, M.N. (Michael), Haas, O.A. (O. A.), Panzer-Grümayer, R. (Renate), Sedek, L. (Lukasz), Szczepa, T. (T.), Caye, A. (Aurélie), Suarez, L. (L.), Cavé, H. (Helene), and Marschalek, R. (Rolf)

Abstract

Chromosomal rearrangements of the human MLL/KMT2A gene are associated with infant, pediatric, adult and therapy-induced acute leukemias. Here we present the data obtained from 2345 acute leukemia patients. Genomic breakpoints within the MLL gene and the involved translocation partner genes (TPGs) were determined and 11 novel TPGs were identified. Thus, a total of 135 different MLL rearrangements have been identified so far, of which 94 TPGs are now characterized at the molecular level. In all, 35 out of these 94 TPGs occur recurrently, but only 9 specific gene fusions account for more than 90% of all illegitimate recombinations of the MLL gene. We observed an age-dependent breakpoint shift with breakpoints localizing within MLL intron 11 associated with acute lymphoblastic leukemia and younger patients, while breakpoints in MLL intron 9 predominate in AML or older patients. The molecular characterization of MLL breakpoints suggests different etiologies in the different age groups and allows the correlation of functional domains of the MLL gene with clinical outcome. This study provides a comprehensive analysis of the MLL recombinome in acute leukemia and demonstrates that the establishment of patient-specific chromosomal fusion sites allows the design of specific PCR primers for minimal residual disease analyses for all patients.

Published
2018
Full Text
View/download PDF

44. Front-line imatinib treatment in children and adolescents with chronic myeloid leukemia: Results from a phase III trial

Author

Suttorp, M, Schulze, P, Glauche, I, Göhring, G, Von Neuhoff, N, Metzler, M, Sedlacek, P, De Bont, E, Balduzzi, A, Lausen, B, Aleinikova, O, Sufliarska, S, Henze, G, Strauss, G, Eggert, A, Kremens, B, Groll, A, Berthold, F, Klein, C, Groß-Wieltsch, U, Sykora, K, Borkhardt, A, Kulozik, A, Schrappe, M, Nowasz, C, Krumbholz, M, Tauer, J, Claviez, A, Harbott, J, Kreipe, H, Schlegelberger, B, Thiede, C, Suttorp, Meinolf, Schulze, Philipp, Glauche, Ingmar, Göhring, Gudrun, Von Neuhoff, Nils, Metzler, Markus, Sedlacek, Petr, De Bont, Eveline S. J. M., Balduzzi, Adriana, Lausen, Birgitte, Aleinikova, Olga, Sufliarska, Sabina, Henze, Günter, Strauss, Gabriele, Eggert, Angelika, Kremens, Bernhard, Groll, Andreas H., Berthold, Frank, Klein, Christoph, Groß-Wieltsch, Ute, Sykora, Karl Walter, Borkhardt, Arndt, Kulozik, Andreas E., Schrappe, Martin, Nowasz, Christina, Krumbholz, Manuela, Tauer, Josephine T., Claviez, Alexander, Harbott, Jochen, Kreipe, Hans H., Schlegelberger, Brigitte, Thiede, Christian, Suttorp, M, Schulze, P, Glauche, I, Göhring, G, Von Neuhoff, N, Metzler, M, Sedlacek, P, De Bont, E, Balduzzi, A, Lausen, B, Aleinikova, O, Sufliarska, S, Henze, G, Strauss, G, Eggert, A, Kremens, B, Groll, A, Berthold, F, Klein, C, Groß-Wieltsch, U, Sykora, K, Borkhardt, A, Kulozik, A, Schrappe, M, Nowasz, C, Krumbholz, M, Tauer, J, Claviez, A, Harbott, J, Kreipe, H, Schlegelberger, B, Thiede, C, Suttorp, Meinolf, Schulze, Philipp, Glauche, Ingmar, Göhring, Gudrun, Von Neuhoff, Nils, Metzler, Markus, Sedlacek, Petr, De Bont, Eveline S. J. M., Balduzzi, Adriana, Lausen, Birgitte, Aleinikova, Olga, Sufliarska, Sabina, Henze, Günter, Strauss, Gabriele, Eggert, Angelika, Kremens, Bernhard, Groll, Andreas H., Berthold, Frank, Klein, Christoph, Groß-Wieltsch, Ute, Sykora, Karl Walter, Borkhardt, Arndt, Kulozik, Andreas E., Schrappe, Martin, Nowasz, Christina, Krumbholz, Manuela, Tauer, Josephine T., Claviez, Alexander, Harbott, Jochen, Kreipe, Hans H., Schlegelberger, Brigitte, and Thiede, Christian

Abstract

A total of 156 patients (age range 1.3-18.0 years, median 13.2 years; 91 (58.3%) male) with newly diagnosed CML (N = 146 chronic phase (CML-CP), N = 3 accelerated phase (CML-AP), N = 7 blastic phase (CML-BP)) received imatinib up-front (300, 400, 500 mg/m 2 , respectively) within a prospective phase III trial. Therapy response, progression-free survival, causes of treatment failure, and side effects were analyzed in 148 children and adolescents with complete data. Event-free survival rate by 18 months for patients in CML-CP (median follow-up time 25 months, range: 1-120) was 97% (95% CI, 94.2-99.9%). According to the 2006 ELN-criteria complete hematologic response by month 3, complete cytogenetic response (CCyR) by month 12, and major molecular response (MMR) by month 18 were achieved in 98, 63, and 59% of the patients, respectively. By month 36, 86% of the patients achieved CCyR and 74% achieved MMR. Thirty-eight patients (27%) experienced imatinib failure because of unsatisfactory response or intolerance (N = 9). In all, 28/148 patients (19%) underwent stem cell transplantation (SCT). In the SCT sub-cohort 2/23 patients diagnosed in CML-CP, 0/1 in CML-AP, and 2/4 in CML-BP, respectively, died of relapse (N = 3) or SCT-related complications (N = 2). This large pediatric trial extends and confirms data from smaller series that first-line imatinib in children is highly effective.

Published
2018

45. The MLL recombinome of acute leukemias in 2017

Author

Hubrecht Institute with UMC, Meyer, C, Burmeister, T, Gröger, D, Tsaur, G, Fechina, L, Renneville, A, Sutton, R, Venn, N C, Emerenciano, M, Pombo-de-Oliveira, M S, Barbieri Blunck, C, Almeida Lopes, B, Zuna, J, Trka, J, Ballerini, P, Lapillonne, H, De Braekeleer, M, Cazzaniga, G, Corral Abascal, L, van der Velden, V H J, Delabesse, E, Park, T S, Oh, S H, Silva, M L M, Lund-Aho, T, Juvonen, V, Moore, A S, Heidenreich, O, Vormoor, J, Zerkalenkova, E, Olshanskaya, Y, Bueno, C, Menendez, P, Teigler-Schlegel, A, Zur Stadt, U, Lentes, J, Göhring, G, Kustanovich, A, Aleinikova, O, Schäfer, B W, Kubetzko, S, Madsen, H O, Gruhn, B, Duarte, X, Gameiro, P, Lippert, E, Bidet, A, Cayuela, J M, Clappier, E, Alonso, C N, Zwaan, C M, van den Heuvel-Eibrink, M M, Izraeli, S, Trakhtenbrot, L, Archer, P, Hancock, J, Möricke, A, Alten, J, Schrappe, M, Stanulla, M, Strehl, S, Attarbaschi, A, Dworzak, M, Haas, O A, Panzer-Grümayer, R, Sedék, L, Szczepański, T, Caye, A, Suarez, L, Cavé, H, Marschalek, R, Hubrecht Institute with UMC, Meyer, C, Burmeister, T, Gröger, D, Tsaur, G, Fechina, L, Renneville, A, Sutton, R, Venn, N C, Emerenciano, M, Pombo-de-Oliveira, M S, Barbieri Blunck, C, Almeida Lopes, B, Zuna, J, Trka, J, Ballerini, P, Lapillonne, H, De Braekeleer, M, Cazzaniga, G, Corral Abascal, L, van der Velden, V H J, Delabesse, E, Park, T S, Oh, S H, Silva, M L M, Lund-Aho, T, Juvonen, V, Moore, A S, Heidenreich, O, Vormoor, J, Zerkalenkova, E, Olshanskaya, Y, Bueno, C, Menendez, P, Teigler-Schlegel, A, Zur Stadt, U, Lentes, J, Göhring, G, Kustanovich, A, Aleinikova, O, Schäfer, B W, Kubetzko, S, Madsen, H O, Gruhn, B, Duarte, X, Gameiro, P, Lippert, E, Bidet, A, Cayuela, J M, Clappier, E, Alonso, C N, Zwaan, C M, van den Heuvel-Eibrink, M M, Izraeli, S, Trakhtenbrot, L, Archer, P, Hancock, J, Möricke, A, Alten, J, Schrappe, M, Stanulla, M, Strehl, S, Attarbaschi, A, Dworzak, M, Haas, O A, Panzer-Grümayer, R, Sedék, L, Szczepański, T, Caye, A, Suarez, L, Cavé, H, and Marschalek, R

Published
2018

46. Worldwide comparison of survival from childhood leukaemia for 1995–2009, by subtype, age, and sex (CONCORD-2): a population-based study of individual data for 89 828 children from 198 registries in 53 countries

Author

Bonaventure, Audrey, Harewood, Rhea, Stiller, Charles A, Gatta, Gemma, Clavel, Jacqueline, Stefan, Daniela C, Carreira, Helena, Spika, Devon, Marcos Gragera, Rafael, Peris Bonet, Rafael, Piñeros, Marion, Sant, Milena, Kuehni, Claudia E, Murphy, Michael F. G, Coleman, Michel P, Allemani, Claudia, Bouzbid, S., Hamdi Chérif, M., Zaidi, Z., Bah, E., Swaminathan, R., Nortje, S. H., El Mistiri, M. M., Bayo, S., Malle, B., Manraj, S. S., Sewpaul Sungkur, R., Fabowale, Null, Ogunbiyi, O. J., Bradshaw, D., Somdyala, N. I. M., Stefan, D. C., Abdel Rahman, M., Jaidane, L., Mokni, M., Kumcher, I., Moreno, F., González, M. S., Laura, E. A., Espinola, S. B., Calabrano, G. H., Carballo Quintero, B., Fita, R., Garcilazo, D. A., Giacciani, P. L., Diumenjo, M. C., Laspada, W. D., Green, M. A., Lanza, M. F., Ibañez, S. G., Lima, C. A., de Oliveira, E. Lobo, Daniel, C., Scandiuzzi, C., De Souza, P. C. F., Melo, C. D., Del Pino, K., Laporte, C., Curado, M. P., de Oliveira, J. C., Veneziano, C. L. A., Veneziano, D. B., Alexandre, T. S., Verdugo, A. S., Azevedo e. Silva, G., Galaz, J. C., Moya, J. A., Herrmann, D. A., Vargas, S., Herrera, V. M., Uribe, C. J., Bravo, L. E., Arias Ortiz, N. E., Jurado, D. M., Yépez, M. C., Galán, Y. H., Torres, P., Martínez Reyes, F., Pérez Meza, M. L., Jaramillo, L., Quinto, R., Cueva, P., Yépez, J. G., Torres Cintrón, C. R., Tortolero Luna, G., Alonso, R., Barrios, E., Nikiforuk, C., Shack, L., Coldman, A. J., Woods, R. R., Noonan, G., Turner, D., Kumar, E., Zhang, B., Mccrate, F. R., Ryan, S., Hannah, H., Dewar, R. A. D., Macintyre, M., Lalany, A., Ruta, M., Marrett, L., Nishri, D. E., Mcclure, C., Vriends, K. A., Bertrand, C., Louchini, R., Robb, K. I., Stuart Panko, H., Demers, S., Wright, S., George, J. T., Shen, X., Brockhouse, J. T., O'Brien, D. K., Ward, K. C., Almon, L., Bates, J., Rycroft, R., Mueller, L., Phillips, C., Brown, H., Cromartie, B., Schwartz, A. G., Vigneau, F., Mackinnon, J. A., Wohler, B., Bayakly, A. R., Clarke, C. A., Glaser, S. L., West, D., Green, M. D., Hernandez, B. Y., Johnson, C. J., Jozwik, D., Charlton, M. E., Lynch, C. F., Huang, B., Tucker, T. C., Deapen, D., Liu, L., Hsieh, M. C., X. C., Wu, Stern, K., Gershman, S. T., Knowlton, R. C., Alverson, J., Copeland, G. E., Rogers, D. B., Lemons, D., Williamson, L. L., Hood, M., Hosain, G. M., Rees, J. R., Pawlish, K. S., Stroup, A., Key, C., Wiggins, C., Kahn, A. R., Schymura, M. J., Leung, G., Rao, C., Giljahn, L., Warther, B., Pate, A., Patil, M., Schubert, S. S., Rubertone, J. J., Slack, S. J., Fulton, J. P., Rousseau, D. L., Janes, T. A., Schwartz, S. M., Bolick, S. W., Hurley, D. M., Richards, J., Whiteside, M. A., Nogueira, L. M., Herget, K., Sweeney, C., Martin, J., Wang, S., Harrelson, D. G., Cheteri, MB Keitheri, Farley, S., Hudson, A. G., Borchers, R., Stephenson, L., Espinoza, J. R., Weir, H. K., Edwards, B. K., Wang, N., Yang, L., Chen, J. S., Song, G. H., X. P., Gu, Zhang, P., H. M., Ge, Zhao, D. L., Zhang, J. H., Zhu, F. D., Tang, J. G., Shen, Y., Wang, J., Q. L., Li, Yang, X. P., Dong, J., Li, W., Cheng, L. P., Chen, J. G., Huang, Q. H., Huang, S. Q., Guo, G. P., Wei, K., Chen, W. Q., Zeng, H., Demetriou, A. V., Pavlou, P., Mang, W. K., Ngan, K. C., Kataki, A. C., Krishnatreya, M., Jayalekshmi, P. A., Sebastian, P., Sapkota, S. D., Verma, Y., Nandakumar, A., Suzanna, E., Keinan Boker, L., Silverman, B. G., Ito, H., Nakagawa, H., Hattori, M., Kaizaki, Y., Sugiyama, H., Utada, M., Katayama, K., Narimatsu, H., Kanemura, S., Koike, T., Miyashiro, I., Yoshii, M., Oki, I., Shibata, A., Matsuda, T., Nimri, O., Ab Manan, A., Pathy, N. Bhoo, Chimedsuren, O., Tuvshingerel, S., Al Khater, A. H. M., Al Eid, H., Jung, K. W., Won, Y. J., Chiang, C. J., Lai, M. S., Suwanrungruang, K., Wiangnon, S., Daoprasert, K., Pongnikorn, D., Geater, S. L., Sriplung, H., Eser, S., Yakut, C. I., Hackl, M., Mühlböck, H., Oberaigner, W., Zborovskaya, A. A., Aleinikova, O. V., Henau, K., Van Eycken, L., Dimitrova, N., Valerianova, Z., Šekerija, M., Zvolský, M., Engholm, G., Storm, H., Innos, K., Mägi, M., Malila, N., Seppä, K., Jégu, J., Velten, M., Cornet, E., Troussard, X., Bouvier, A. M., Faivre, J., Guizard, A. V., Bouvier, V., Launoy, G., Arveux, P., Maynadié, M., Mounier, M., Fournier, E., Woronoff, A. S., Daoulas, M., Clavel, J., Le Guyader Peyrou, S., Monnereau, A., Trétarre, B., Colonna, M., Cowppli Bony, A., Molinié, F., Bara, S., Degré, D., Ganry, O., Lapôtre Ledoux, B., Grosclaude, P., Estève, J., Bray, F., Piñeros, M., Sassi, F., Stabenow, R., Eberle, A., Erb, C., Nennecke, A., Kieschke, J., Sirri, E., Kajueter, H., Emrich, K., Zeissig, S. R., Holleczek, B., Eisemann, N., Katalinic, A., Brenner, H., Asquez, R. A., Kumar, V., Ólafsdóttir, E. J., Tryggvadóttir, L., Comber, H., Walsh, P. M., Sundseth, H., Devigili, E., Mazzoleni, G., Giacomin, A., Bella, F., Castaing, M., Sutera, A., Gola, G., Ferretti, S., Serraino, D., Zucchetto, A., Lillini, R., Vercelli, M., Busco, S., Pannozzo, F., Vitarelli, S., Ricci, P., Pascucci, C., Autelitano, M., Cirilli, C., Federico, M., Fusco, M., Vitale, M. F., Usala, M., Cusimano, R., Mazzucco, W., Michiara, M., Sgargi, P., Maule, MILENA MARIA, Sacerdote, C., Tumino, R., Di Felice, E., Vicentini, M., Falcini, F., Cremone, L., Budroni, M., Cesaraccio, R., Contrino, M. L., Tisano, F., Fanetti, A. C., Maspero, S., Candela, G., Scuderi, T., Gentilini, M. A., Piffer, S., Rosso, S., Sacchetto, Lidia, Caldarella, A., La Rosa, F., Stracci, F., Contiero, P., Tagliabue, G., Dei Tos, A. P., Zorzi, M., Zanetti, R., Baili, P., Berrino, F., Gatta, G., Sant, M., Capocaccia, R., De Angelis, R., Liepina, E., Maurina, A., Smailyte, G., Agius, D., Calleja, N., Siesling, S., Visser, O., Larønningen, S., Møller, B., Dyzmann Sroka, A., Trojanowski, M., Gózdz, S., Mezyk, R., Gradalska Lampart, M., Radziszewska, A. U., Didkowska, J. A., Wojciechowska, U., Blaszczyk, J., Kepska, K., Bielska Lasota, M., Kwiatkowska, K., Forjaz, G., Rego, R. A., Bastos, J., Silva, M. A., Antunes, L., Bento, M. J., Mayer da Silva, A., Miranda, A., Coza, D., Todescu, A. I., Valkov, M. Y., Adamcik, J., Safaei Diba, C., Primic Žakelj, M., Žagar, T., Stare, J., Almar, E., Mateos, A., Quirós, J. R., Bidaurrazaga, J., Larrañaga, N., Díaz García, J. M., Marcos, A. I., Marcos Gragera, R., Vilardell Gil, M. L., Molina, E., Sánchez, M. J., Sureda, P. Franch, Montserrat, M. Ramos, Chirlaque, M. D., Navarro, C., Ardanaz, E. E., Moreno Iribas, C. C., Fernández Delgado, R., Peris Bonet, R., Galceran, J., Khan, S., Lambe, M., Camey, B., Bouchardy, C., Usel, M., Ess, S. M., Herrmann, C., Bulliard, J. L., Maspoli Conconi, M., Frick, H., Kuehni, C. E., Schindler, M., Bordoni, A., Spitale, A., Chiolero, A., Konzelmann, I., Dehler, S. I., Matthes, K. L., Rashbass, J., Stiller, C. A., Fitzpatrick, D., Gavin, A., Bannon, F., Black, R. J., Brewster, D. H., Huws, D. W., White, C., Finan, P., Allemani, C., Bonaventure, A., Carreira, H., Coleman, M. P., Di Carlo, V., Harewood, R., Liu, K., Matz, M., Montel, L., Nikšic, M., Rachet, B., Sanz, N., Spika, D., Stephens, R., Peake, M., Murphy, M. F. G., Chalker, E., Newman, L., Baker, D., Soeberg, M. J., Aitken, J., Scott, C., Stokes, B. C., Venn, A., Farrugia, H., Giles, G. G., Threlfall, T., Currow, D., You, H., Hendrix, J., Lewis, C., Latorre, M. R. D. O., and Tanaka, L. F.

Subjects
Hematology
Published
2017

47. Worldwide comparison of ovarian cancer survival: Histological group and stage at diagnosis (CONCORD-2)

Author

Matz, M., Coleman, M., Carreira, H., Salmerã³n, D., Chirlaque, M., Allemani, C., Bouzbid, S., Hamdi-chérif, M., Zaidi, Z., Bah, E., Swaminathan, R., Nortje, S., El Mistiri, M., Bayo, S., Malle, B., Manraj, S., Sewpaul-sungkur, R., Fabowale, A., Ogunbiyi, O., Bradshaw, D., Somdyala, N., Stefan, D., Abdel-rahman, M., Jaidane, L., Mokni, M., Kumcher, I., Moreno, F., González, M., Laura, E., Espinola, S., Calabrano, G., Carballo Quintero, B., Fita, R., Garcilazo, D., Giacciani, P., Diumenjo, M., Laspada, W., Green, M., Lanza, M., Ibañez, S., Lima, C., Lobo De Oliveira, E., Daniel, C., Scandiuzzi, C., De Souza, P., Melo, C., Del Pino, K., Laporte, C., Curado, M., De Oliveira, J., Veneziano, C., Veneziano, D., Latorre, M., Tanaka, L., Azevedo E. Silva, G., Galaz, J., Moya, J., Herrmann, D., Vargas, S., Herrera, V., Uribe, C., Bravo, L., Arias-ortiz, N., Jurado, D., Yépez, M., Galán, Y., Torres, P., Martínez-reyes, F., Pérez-meza, M., Jaramillo, L., Quinto, R., Cueva, P., Yépez, J., Torres-cintrón, C., Tortolero-luna, G., Alonso, R., Barrios, E., Nikiforuk, C., Shack, L., Coldman, A., Woods, R., Noonan, G., Turner, D., Kumar, E., Zhang, B., Mccrate, F., Ryan, S., Hannah, H., Dewar, R., Macintyre, M., Lalany, A., Ruta, M., Marrett, L., Nishri, D., Mcclure, C., Vriends, K., Bertrand, C., Louchini, R., Robb, K., Stuart-panko, H., Demers, S., Wright, S., George, J., Shen, X., Brockhouse, J., O'Brien, D., Ward, K., Almon, L., Bates, J., Rycroft, R., Mueller, L., Phillips, C., Brown, H., Cromartie, B., Schwartz, A., Vigneau, F., Mackinnon, J., Wohler, B., Bayakly, A., Clarke, C., Glaser, S., West, D., Hernandez, B., Johnson, C., Jozwik, D., Charlton, M., Lynch, C., Huang, B., Tucker, T., Deapen, D., Liu, L., Hsieh, M., Xc, W., Stern, K., Gershman, S., Knowlton, R., Alverson, J., Copeland, G., Rogers, D., Lemons, D., Williamson, L., Hood, M., Hosain, G., Rees, J., Pawlish, K., Stroup, A., Key, C., Wiggins, C., Kahn, A., Schymura, M., Leung, G., Rao, C., Giljahn, L., Warther, B., Pate, A., Patil, M., Schubert, S., Rubertone, J., Slack, S., Fulton, J., Rousseau, D., Janes, Ta:, S., Bolick, S., Hurley, D., Richards, J., Whiteside, M., Nogueira, L., Herget, K., Sweeney, C., Martin, J., Wang, S., Harrelson, D., Keitheri Cheteri, M., Farley, S., Hudson, A., Borchers, R., Stephenson, L., Espinoza, J., Weir, H., Edwards, B., Wang, N., Yang, L., Chen, J., Song, G., Xp, G., Zhang, P., Hm, G., Zhao, D., Zhang, J., Zhu, F., Tang, J., Shen, Y., Wang, J., Ql, L., Yang, X., Dong, J., Li, W., Cheng, L., Huang, Q., Huang, S., Guo, G., Wei, K., Chen, W., Zeng, H., Demetriou, A., Pavlou, P., Mang, W., Ngan, K., Kataki, A., Krishnatreya, M., Jayalekshmi, P., Sebastian, P., Sapkota, S., Verma, Y., Nandakumar, A., Suzanna, E., Keinan-boker, L., Silverman, B., Ito, H., Nakagawa, H., Hattori, M., Kaizaki, Y., Sugiyama, H., Utada, M., Katayama, K., Narimatsu, H., Kanemura, S., Koike, T., Miyashiro, I., Yoshii, M., Oki, I., Shibata, A., Matsuda, T., Nimri, O., Ab Manan, A., Bhoo-pathy, N., Tuvshingerel, S., Chimedsuren, O., Al Khater, A., Al-eid, H., Jung, K., Won, Y., Chiang, C., Lai, M., Suwanrungruang, K., Wiangnon, S., Daoprasert, K., Pongnikorn, D., Geater, S., Sriplung, H., Eser, S., Yakut, C., Hackl, M., Mühlböck, H., Oberaigner, W., Zborovskaya, A., Aleinikova, O., Henau, K., Van Eycken, L., Dimitrova, N., Valerianova, Z., Šekerija, M., Zvolský, M., Engholm, G., Storm, H., Innos, K., Mägi, M., Malila, N., Seppä, K., Jégu, J., Velten, M., Cornet, E., Troussard, X., Bouvier, A., Faivre, J., Guizard, A., Bouvier, V., Launoy, G., Arveux, P., Maynadié, M., Mounier, M., Fournier, E., Woronoff, A., Daoulas, M., Clavel, J., Le Guyader-peyrou, S., Monnereau, A., Trétarre, B., Colonna, M., Cowppli-bony, A., Molinié, F., Bara, S., Degré, D., Ganry, O., Lapôtre-ledoux, B., Grosclaude, P., Estève, J., Bray, F., Piñeros, M., Sassi, F., Stabenow, R., Eberle, A., Erb, C., Nennecke, A., Kieschke, J., Sirri, E., Kajueter, H., Emrich, K., Zeissig, S., Holleczek, B., Eisemann, N., Katalinic, A., Brenner, H., Asquez, R., Kumar, V., Ólafsdóttir, E., Tryggvadóttir, L., Comber, H., Walsh, P., Sundseth, H., Devigili, E., Mazzoleni, G., Giacomin, A., Bella, F., Castaing, M., Sutera, A., Gola, G., Ferretti, S., Serraino, D., Zucchetto, A., Lillini, R., Vercelli, M., Busco, S., Pannozzo, F., Vitarelli, S., Ricci, P., Pascucci, C., Autelitano, M., Cirilli, C., Federico, M., Fusco, M., Vitale, M., Usala, M., Cusimano, R., Mazzucco, W., Michiara, M., Sgargi, P., Maule, M., Sacerdote, C., Tumino, R., Di Felice, E., Vicentini, M., Falcini, F., Cremone, L., Budroni, M., Cesaraccio, R., Contrino, M., Tisano, F., Fanetti, A., Maspero, S., Candela, G., Scuderi, T., Gentilini, M., Piffer, S., Rosso, S., Sacchetto, L., Caldarella, A., La Rosa, F., Stracci, F., Contiero, P., Tagliabue, G., Dei Tos, A., Zorzi, M., Zanetti, R., Baili, P., Berrino, F., Gatta, G., Sant, M., Capocaccia, R., De Angelis, R., Liepina, E., Maurina, A., Smailyte, G., Agius, D., Calleja, N., Siesling, S., Visser, O., Larønningen, S., Møller, B., Dyzmann-sroka, A., Trojanowski, M., Góźdż, S., Mężyk, R., Grądalska-lampart, M., Radziszewska, A., Didkowska, J., Wojciechowska, U., Błaszczyk, J., Kępska, K., Bielska-lasota, M., Kwiatkowska, K., Forjaz, G., Rego, R., Bastos, J., Silva, M., Antunes, L., Bento, M., Mayer-da-silva, A., Miranda, A., Coza, D., Todescu, A., Valkov, M., Adamcik, J., Safaei Diba, C., Primic-žakelj, M., Žagar, T., Stare, J., Almar, E., Mateos, A., Quirós, J., Bidaurrazaga, J., Larrañaga, N., Díaz García, J., Marcos, A., Marcos-gragera, R., Vilardell Gil, M., Molina, E., Sánchez, M., Franch Sureda, P., Ramos Montserrat, M., Navarro, C., Ardanaz, E., Moreno-iribas, C., Fernández-delgado, R., Peris-bonet, R., Galceran, J., Khan, S., Lambe, M., Camey, B., Bouchardy, C., Usel, M., Ess, S., Herrmann, C., Bulliard, J., Maspoli-conconi, M., Frick, H., Kuehni, C., Schindler, M., Bordoni, A., Spitale, A., Chiolero, A., Konzelmann, I., Dehler, S., Matthes, K., Rashbass, J., Stiller, C., Fitzpatrick, D., Gavin, A., Bannon, F., Black, R., Brewster, D., Huws, D., White, C., Finan, P., Bonaventure, A., Di Carlo, V., Harewood, R., Liu, K., Montel, L., Nikšić, M., Rachet, B., Sanz, N., Spika, D., Stephens, R., Peake, M., Chalker, E., Newman, L., Baker, D., Soeberg, M., Aitken, J., Scott, C., Stokes, B., Venn, A., Farrugia, H., Giles, G., Threlfall, T., Currow, D., You, H., Hendrix, J., Lewis, C., Matz, M, Coleman, M, Carreira, H, Salmeròn, D, Chirlaque, M, Allemani, C, and Mazzucco, W

Subjects
0301 basic medicine, Oncology, Settore MED/42 - Igiene Generale E Applicata, 0302 clinical medicine, morphology, 80 and over, Stage (cooking), Aged, 80 and over, Ovarian Neoplasms, education.field_of_study, epidemiology, histology, ovarian cancer, stage, survival, Adolescent, Adult, Aged, Female, Humans, Middle Aged, Neoplasm Staging, Obstetrics and Gynecology, Transitional cell carcinoma, 030220 oncology & carcinogenesis, Clear cell carcinoma, Human, medicine.medical_specialty, Population, Socio-culturale, Article, 03 medical and health sciences, Internal medicine, medicine, ovarian cancer, epidemiology, survival, stage, morphology, histology, education, Cancer staging, Gynecology, business.industry, Ovarian Neoplasm, Cancer, medicine.disease, Cancer registry, 030104 developmental biology, Ovarian cancer, business
Abstract

Objective Ovarian cancer comprises several histological groups with widely differing levels of survival. We aimed to explore international variation in survival for each group to help interpret international differences in survival from all ovarian cancers combined. We also examined differences in stage-specific survival. Methods The CONCORD programme is the largest population-based study of global trends in cancer survival, including data from 60 countries for 695,932 women (aged 15–99years) diagnosed with ovarian cancer during 1995–2009. We defined six histological groups: type I epithelial, type II epithelial, germ cell, sex cord-stromal, other specific non-epithelial and non-specific morphology, and estimated age-standardised 5-year net survival for each country by histological group. We also analysed data from 67 cancer registries for 233,659 women diagnosed from 2001 to 2009, for whom information on stage at diagnosis was available. We estimated age-standardised 5-year net survival by stage at diagnosis (localised or advanced). Results Survival from type I epithelial ovarian tumours for women diagnosed during 2005–09 ranged from 40 to 70%. Survival from type II epithelial tumours was much lower (20–45%). Survival from germ cell tumours was higher than that of type II epithelial tumours, but also varied widely between countries. Survival for sex-cord stromal tumours was higher than for the five other groups. Survival from localised tumours was much higher than for advanced disease (80% vs. 30%). Conclusions There is wide variation in survival between histological groups, and stage at diagnosis remains an important factor in ovarian cancer survival. International comparisons of ovarian cancer survival should incorporate histology.

Published
2017

49. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries

Author

Allemani, Claudia, primary, Matsuda, Tomohiro, additional, Di Carlo, Veronica, additional, Harewood, Rhea, additional, Matz, Melissa, additional, Nikšić, Maja, additional, Bonaventure, Audrey, additional, Valkov, Mikhail, additional, Johnson, Christopher J, additional, Estève, Jacques, additional, Ogunbiyi, Olufemi J, additional, Azevedo e Silva, Gulnar, additional, Chen, Wan-Qing, additional, Eser, Sultan, additional, Engholm, Gerda, additional, Stiller, Charles A, additional, Monnereau, Alain, additional, Woods, Ryan R, additional, Visser, Otto, additional, Lim, Gek Hsiang, additional, Aitken, Joanne, additional, Weir, Hannah K, additional, Coleman, Michel P, additional, Bouzbid, S, additional, Hamdi-Chérif, M, additional, Zaidi, Z, additional, Meguenni, K, additional, Regagba, D, additional, Bayo, S, additional, Cheick Bougadari, T, additional, Manraj, S S, additional, Bendahhou, K, additional, Fabowale, A, additional, Bradshaw, D, additional, Somdyala, N I M, additional, Kumcher, I, additional, Moreno, F, additional, Calabrano, G H, additional, Espinola, S B, additional, Carballo Quintero, B, additional, Fita, R, additional, Diumenjo, M C, additional, Laspada, W D, additional, Ibañez, S G, additional, Lima, C A, additional, De Souza, P C F, additional, Del Pino, K, additional, Laporte, C, additional, Curado, M P, additional, de Oliveira, J C, additional, Veneziano, C L A, additional, Veneziano, D B, additional, Latorre, M R D O, additional, Tanaka, L F, additional, Rebelo, M S, additional, Santos, M O, additional, Galaz, J C, additional, Aparicio Aravena, M, additional, Sanhueza Monsalve, J, additional, Herrmann, D A, additional, Vargas, S, additional, Herrera, V M, additional, Uribe, C J, additional, Bravo, L E, additional, Garcia, L S, additional, Arias-Ortiz, N E, additional, Morantes, D, additional, Jurado, D M, additional, Yépez Chamorro, M C, additional, Delgado, S, additional, Ramirez, M, additional, Galán Alvarez, Y H, additional, Torres, P, additional, Martínez-Reyes, F, additional, Jaramillo, L, additional, Quinto, R, additional, Castillo, J, additional, Mendoza, M, additional, Cueva, P, additional, Yépez, J G, additional, Bhakkan, B, additional, Deloumeaux, J, additional, Joachim, C, additional, Macni, J, additional, Carrillo, R, additional, Shalkow Klincovstein, J, additional, Rivera Gomez, R, additional, Poquioma, E, additional, Tortolero-Luna, G, additional, Zavala, D, additional, Alonso, R, additional, Barrios, E, additional, Eckstrand, A, additional, Nikiforuk, C, additional, Noonan, G, additional, Turner, D, additional, Kumar, E, additional, Zhang, B, additional, McCrate, F R, additional, Ryan, S, additional, MacIntyre, M, additional, Saint-Jacques, N, additional, Nishri, D E, additional, McClure, C A, additional, Vriends, K A, additional, Kozie, S, additional, Stuart-Panko, H, additional, Freeman, T, additional, George, J T, additional, Brockhouse, J T, additional, O'Brien, D K, additional, Holt, A, additional, Almon, L, additional, Kwong, S, additional, Morris, C, additional, Rycroft, R, additional, Mueller, L, additional, Phillips, C E, additional, Brown, H, additional, Cromartie, B, additional, Schwartz, A G, additional, Vigneau, F, additional, Levin, G M, additional, Wohler, B, additional, Bayakly, R, additional, Ward, K C, additional, Gomez, S L, additional, McKinley, M, additional, Cress, R, additional, Green, M D, additional, Miyagi, K, additional, Ruppert, L P, additional, Lynch, C F, additional, Huang, B, additional, Tucker, T C, additional, Deapen, D, additional, Liu, L, additional, Hsieh, M C, additional, Wu, X C, additional, Schwenn, M, additional, Gershman, S T, additional, Knowlton, R C, additional, Alverson, G, additional, Copeland, G E, additional, Bushhouse, S, additional, Rogers, D B, additional, Jackson-Thompson, J, additional, Lemons, D, additional, Zimmerman, H J, additional, Hood, M, additional, Roberts-Johnson, J, additional, Rees, J R, additional, Riddle, B, additional, Pawlish, K S, additional, Stroup, A, additional, Key, C, additional, Wiggins, C, additional, Kahn, A R, additional, Schymura, M J, additional, Radhakrishnan, S, additional, Rao, C, additional, Giljahn, L K, additional, Slocumb, R M, additional, Espinoza, R E, additional, Khan, F, additional, Aird, K G, additional, Beran, T, additional, Rubertone, J J, additional, Slack, S J, additional, Garcia, L, additional, Rousseau, D L, additional, Janes, T A, additional, Schwartz, S M, additional, Bolick, S W, additional, Hurley, D M, additional, Whiteside, M A, additional, Miller-Gianturco, P, additional, Williams, M A, additional, Herget, K, additional, Sweeney, C, additional, Johnson, A T, additional, Keitheri Cheteri, M B, additional, Migliore Santiago, P, additional, Blankenship, S E, additional, Farley, S, additional, Borchers, R, additional, Malicki, R, additional, Espinoza, J R, additional, Grandpre, J, additional, Wilson, R, additional, Edwards, B K, additional, Mariotto, A, additional, Lei, Y, additional, Wang, N, additional, Chen, J S, additional, Zhou, Y, additional, He, Y T, additional, Song, G H, additional, Gu, X P, additional, Mei, D, additional, Mu, H J, additional, Ge, H M, additional, Wu, T H, additional, Li, Y Y, additional, Zhao, D L, additional, Jin, F, additional, Zhang, J H, additional, Zhu, F D, additional, Junhua, Q, additional, Yang, Y L, additional, Jiang, C X, additional, Biao, W, additional, Wang, J, additional, Li, Q L, additional, Yi, H, additional, Zhou, X, additional, Dong, J, additional, Li, W, additional, Fu, F X, additional, Liu, S Z, additional, Chen, J G, additional, Zhu, J, additional, Li, Y H, additional, Lu, Y Q, additional, Fan, M, additional, Huang, S Q, additional, Guo, G P, additional, Zhaolai, H, additional, Wei, K, additional, Zeng, H, additional, Demetriou, A V, additional, Mang, W K, additional, Ngan, K C, additional, Kataki, A C, additional, Krishnatreya, M, additional, Jayalekshmi, P A, additional, Sebastian, P, additional, Nandakumar, A, additional, Malekzadeh, R, additional, Roshandel, G, additional, Keinan-Boker, L, additional, Silverman, B G, additional, Ito, H, additional, Nakagawa, H, additional, Sato, M, additional, Tobori, F, additional, Nakata, I, additional, Teramoto, N, additional, Hattori, M, additional, Kaizaki, Y, additional, Moki, F, additional, Sugiyama, H, additional, Utada, M, additional, Nishimura, M, additional, Yoshida, K, additional, Kurosawa, K, additional, Nemoto, Y, additional, Narimatsu, H, additional, Sakaguchi, M, additional, Kanemura, S, additional, Naito, M, additional, Narisawa, R, additional, Miyashiro, I, additional, Nakata, K, additional, Sato, S, additional, Yoshii, M, additional, Oki, I, additional, Fukushima, N, additional, Shibata, A, additional, Iwasa, K, additional, Ono, C, additional, Nimri, O, additional, Jung, K W, additional, Won, Y J, additional, Alawadhi, E, additional, Elbasmi, A, additional, Ab Manan, A, additional, Adam, F, additional, Sanjaajmats, E, additional, Tudev, U, additional, Ochir, C, additional, Al Khater, A M, additional, El Mistiri, M M, additional, Teo, Y Y, additional, Chiang, C J, additional, Lee, W C, additional, Buasom, R, additional, Sangrajrang, S, additional, Kamsa-ard, S, additional, Wiangnon, S, additional, Daoprasert, K, additional, Pongnikorn, D, additional, Leklob, A, additional, Sangkitipaiboon, S, additional, Geater, S L, additional, Sriplung, H, additional, Ceylan, O, additional, Kög, I, additional, Dirican, O, additional, Köse, T, additional, Gurbuz, T, additional, Karaşahin, F E, additional, Turhan, D, additional, Aktaş, U, additional, Halat, Y, additional, Yakut, C I, additional, Altinisik, M, additional, Cavusoglu, Y, additional, Türkköylü, A, additional, Üçüncü, N, additional, Hackl, M, additional, Zborovskaya, A A, additional, Aleinikova, O V, additional, Henau, K, additional, Van Eycken, L, additional, Valerianova, Z, additional, Yordanova, M R, additional, Šekerija, M, additional, Dušek, L, additional, Zvolský, M, additional, Storm, H, additional, Innos, K, additional, Mägi, M, additional, Malila, N, additional, Seppä, K, additional, Jégu, J, additional, Velten, M, additional, Cornet, E, additional, Troussard, X, additional, Bouvier, A M, additional, Guizard, A V, additional, Bouvier, V, additional, Launoy, G, additional, Arveux, P, additional, Maynadié, M, additional, Mounier, M, additional, Woronoff, A S, additional, Daoulas, M, additional, Robaszkiewicz, M, additional, Clavel, J, additional, Goujon, S, additional, Lacour, B, additional, Baldi, I, additional, Pouchieu, C, additional, Amadeo, B, additional, Coureau, G, additional, Orazio, S, additional, Preux, P M, additional, Rharbaoui, F, additional, Marrer, E, additional, Trétarre, B, additional, Colonna, M, additional, Delafosse, P, additional, Ligier, K, additional, Plouvier, S, additional, Cowppli-Bony, A, additional, Molinié, F, additional, Bara, S, additional, Ganry, O, additional, Lapôtre-Ledoux, B, additional, Grosclaude, P, additional, Bossard, N, additional, Uhry, Z, additional, Bray, F, additional, Piñeros, M, additional, Stabenow, R, additional, Wilsdorf-Köhler, H, additional, Eberle, A, additional, Luttmann, S, additional, Löhden, I, additional, Nennecke, A L, additional, Kieschke, J, additional, Sirri, E, additional, Emrich, K, additional, Zeissig, S R, additional, Holleczek, B, additional, Eisemann, N, additional, Katalinic, A, additional, Asquez, R A, additional, Kumar, V, additional, Petridou, E, additional, Ólafsdóttir, E J, additional, Tryggvadóttir, L, additional, Clough-Gorr, K, additional, Walsh, P M, additional, Sundseth, H, additional, Mazzoleni, G, additional, Vittadello, F, additional, Coviello, E, additional, Cuccaro, F, additional, Galasso, R, additional, Sampietro, G, additional, Giacomin, A, additional, Magoni, M, additional, Ardizzone, A, additional, D'Argenzio, A, additional, Castaing, M, additional, Grosso, G, additional, Lavecchia, A M, additional, Sutera Sardo, A, additional, Gola, G, additional, Gatti, L, additional, Ricci, P, additional, Ferretti, S, additional, Serraino, D, additional, Zucchetto, A, additional, Celesia, M V, additional, Filiberti, R A, additional, Pannozzo, F, additional, Melcarne, A, additional, Quarta, F, additional, Russo, A G, additional, Carrozzi, G, additional, Cirilli, C, additional, Cavalieri d'Oro, L, additional, Rognoni, M, additional, Fusco, M, additional, Vitale, M F, additional, Usala, M, additional, Cusimano, R, additional, Mazzucco, W, additional, Michiara, M, additional, Sgargi, P, additional, Boschetti, L, additional, Borciani, E, additional, Seghini, P, additional, Maule, M M, additional, Merletti, F, additional, Tumino, R, additional, Mancuso, P, additional, Vicentini, M, additional, Cassetti, T, additional, Sassatelli, R, additional, Falcini, F, additional, Giorgetti, S, additional, Caiazzo, A L, additional, Cavallo, R, additional, Cesaraccio, R, additional, Pirino, D R, additional, Contrino, M L, additional, Tisano, F, additional, Fanetti, A C, additional, Maspero, S, additional, Carone, S, additional, Mincuzzi, A, additional, Candela, G, additional, Scuderi, T, additional, Gentilini, M A, additional, Piffer, S, additional, Rosso, S, additional, Barchielli, A, additional, Caldarella, A, additional, Bianconi, F, additional, Stracci, F, additional, Contiero, P, additional, Tagliabue, G, additional, Rugge, M, additional, Zorzi, M, additional, Beggiato, S, additional, Brustolin, A, additional, Berrino, F, additional, Gatta, G, additional, Sant, M, additional, Buzzoni, C, additional, Mangone, L, additional, Capocaccia, R, additional, De Angelis, R, additional, Zanetti, R, additional, Maurina, A, additional, Pildava, S, additional, Lipunova, N, additional, Vincerževskiené, I, additional, Agius, D, additional, Calleja, N, additional, Siesling, S, additional, Larønningen, S, additional, Møller, B, additional, Dyzmann-Sroka, A, additional, Trojanowski, M, additional, Góźdź, S, additional, Mężyk, R, additional, Mierzwa, T, additional, Molong, L, additional, Rachtan, J, additional, Szewczyk, S, additional, Błaszczyk, J, additional, Kępska, K, additional, Kościańska, B, additional, Tarocińska, K, additional, Zwierko, M, additional, Drosik, K, additional, Maksimowicz, K M, additional, Purwin-Porowska, E, additional, Reca, E, additional, Wójcik-Tomaszewska, J, additional, Tukiendorf, A, additional, Grądalska-Lampart, M, additional, Radziszewska, A U, additional, Gos, A, additional, Talerczyk, M, additional, Wyborska, M, additional, Didkowska, J A, additional, Wojciechowska, U, additional, Bielska-Lasota, M, additional, Forjaz de Lacerda, G, additional, Rego, R A, additional, Bastos, J, additional, Silva, M A, additional, Antunes, L, additional, Laranja Pontes, J, additional, Mayer-da-Silva, A, additional, Miranda, A, additional, Blaga, L M, additional, Coza, D, additional, Gusenkova, L, additional, Lazarevich, O, additional, Prudnikova, O, additional, Vjushkov, D M, additional, Egorova, A G, additional, Orlov, A E, additional, Kudyakov, L A, additional, Pikalova, L V, additional, Adamcik, J, additional, Safaei Diba, C, additional, Primic-Žakelj, M, additional, Zadnik, V, additional, Larrañaga, N, additional, Lopez de Munain, A, additional, Herrera, A A, additional, Redondas, R, additional, Marcos-Gragera, R, additional, Vilardell Gil, M L, additional, Molina, E, additional, Sánchez Perez, M J, additional, Franch Sureda, P, additional, Ramos Montserrat, M, additional, Chirlaque, M D, additional, Navarro, C, additional, Ardanaz, E E, additional, Guevara, M M, additional, Fernández-Delgado, R, additional, Peris-Bonet, R, additional, Carulla, M, additional, Galceran, J, additional, Alberich, C, additional, Vicente-Raneda, M, additional, Khan, S, additional, Pettersson, D, additional, Dickman, P, additional, Avelina, I, additional, Staehelin, K, additional, Camey, B, additional, Bouchardy, C, additional, Schaffar, R, additional, Frick, H, additional, Herrmann, C, additional, Bulliard, J L, additional, Maspoli-Conconi, M, additional, Kuehni, C E, additional, Redmond, S M, additional, Bordoni, A, additional, Ortelli, L, additional, Chiolero, A, additional, Konzelmann, I, additional, Matthes, K L, additional, Rohrmann, S, additional, Broggio, J, additional, Rashbass, J, additional, Fitzpatrick, D, additional, Gavin, A, additional, Clark, D I, additional, Deas, A J, additional, Huws, D W, additional, White, C, additional, Montel, L, additional, Rachet, B, additional, Turculet, A D, additional, Stephens, R, additional, Chalker, E, additional, Phung, H, additional, Walton, R, additional, You, H, additional, Guthridge, S, additional, Johnson, F, additional, Gordon, P, additional, D'Onise, K, additional, Priest, K, additional, Stokes, B C, additional, Venn, A, additional, Farrugia, H, additional, Thursfield, V, additional, Dowling, J, additional, Currow, D, additional, Hendrix, J, additional, and Lewis, C, additional

Published
2018
Full Text
View/download PDF

50. Efficiency of the ALL-MB-2002 protocol in children with acute lymphoblastic leukemia

Author

Rumyantseva, Y. V., Karachunsky, A. I., Aleinikova, O. V., Fechina, L. G., Shamardinal, A. V., Litvinov, D. V., Ponomareva, N. I., Boichenko, E. G., Dudkin, S. A., Streneva, O. V., Kondratchik, K. L., Mansurova, E. G., Minkina, L. M., Lapotentova, E. S., Inyushkina, E. V., Yudina, N. B., Pavlova, G. P., Zhukovskaya, E. V., Khlebnikova, O. P., Lagoiko, S. N., Basharova, E. V., Denisov, R. E., Zlobina, V. D., Banshchikova, E. S., Aslanyan, K. S., Kondakova, E. V., Tselousova, Myakova, N. V., Turobova, T. V., Ryskal, O. V., Chipsanova, N. F., Varfolomeyeva, S. R., and Rumyantsev, A. G.

Subjects
Male, Adolescent, Dose-Response Relationship, Drug, lcsh:R, Age Factors, Infant, lcsh:Medicine, acute lymphoblastic leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Disease-Free Survival, Drug Administration Schedule, Russia, efficiency of therapy, children, Recurrence, Child, Preschool, Antineoplastic Combined Chemotherapy Protocols, Humans, Female, Child
Abstract

Aim. To evaluate the efficiency of the original ALL-MB-2002 protocol within the multicenter study of treatment of acute lymphoblastic leukemia (ALL) in children. Subjects and methods. A total of 1873 primary patients with ALL aged 1 to 18 years, of whom 1544 patients were enrolled in this study, were notified at 36 clinics of Russia and Belarus from April 15, 2002, to January 1, 2008. Results. With the median observation of 4.12 years, 7-year event-free survival (EFS) was 73±13%; overall survival (OS) 78±2%; relapse-free survival 82±1%. The rates of EFS and OS were equal and amounted to 76±2 and 80±2% in the standard-risk group (SRG) and intermediate-risk group (ImRG), respectively. In the high-risk group (HRG) patients, EFS and OS were as high as 30±6 and 37±6%, respectively. The frequency of relapses with central nervous system lesion was as much as 4.7% in all the patients, 6-year cumulative risk for isolated neurorecurrences being 2.5% in the SRG patients. Adolescents, patients with the baseline leukocytosis (more than 100109/l), and those with a splenic size of over 4 cm or more from the costal arch margin had substantially worse survival rates. A poor early response to therapy (on induction days 8 and 15) was also associated with its lower efficiency. Conclusion. Despite a considerable rise in the number of centers and a slight increase in the intensity of therapy, the results of the new ALL-MB-2002 protocol are as minimum equivalents obtained in the use of the previous ALL-MB-91 protocol. A significant improvement in the overall results of therapy and a reduction in the cumulative risk for isolated neurorecurrences were noted in the ImRG patients.

Published
2010

Catalog

Books, media, physical & digital resources
See catalog results